Introduction {#Sec1}
============

Intravenous immunoglobulins (IVIg) are gamma globulins purified from the pooled plasma of thousands of donors, typically containing more than 95% of unmodified immunoglobulin G (IgG) and only trace amounts of IgA or IgM. Immune globulin products from human plasma were first used in 1952 to treat immune deficiencies. About 30 years later, Paul Imbach observed that patients with immune thrombocytopenia and agammaglobulinemia receiving immunoglobulins as immune replacement therapy recovered from their thrombocytopenia \[[@CR1]\]. This was the first observation to suggest treatment of autoimmune diseases with IVIg. Later on, the ability to administer large quantities of immunoglobulin intravenously was gained owing to technological advances, among them the improvement in plasma fractionation. As a result, IVIg slowly became an important treatment option in a number of diseases beyond primary immune deficiencies, including autoimmune and acute inflammatory conditions, most of them off-label indications. These indications have crossed over into almost every medical specialty. The US Food and Drug Administration (FDA) has approved the use of IVIg for the following six conditions: primary immunodeficiencies, immune thrombocytopenic purpura (ITP), Kawasaki disease, hematopoietic stem cell transplantation, chronic B cell lymphocytic leukemia, and pediatric HIV. Many off-label indications have emerged; some of these new indications for IVIg are based on solid clinical evidence; others are based on relatively few data or anecdotal reports (case series, case reports). This lack of firm evidence is due to the difficulty in performing appropriate clinical trials in diseases with low prevalence. There is a need for an evidence-based guidance for the use of IVIg to help improve patient care consistency.

Another issue is the efficacy of different preparations of IVIg. The FDA has recommended the use of particular preparations of IVIg for each labeled indication in accordance to the specific preparation used to demonstrate a beneficial effect. Of course, there is selection bias since generally only a few preparations have been tested for a given disease. This is in recognition of the difficulty to reproduce the properties of an IVIg preparation, which may vary from one manufacturer to the other due to differences in the donor population, number of donors, period of donation, production methods, virus/bacteria inactivation methods, etc. IVIg properties may also vary from batch to batch made by the same manufacturer, complicating homogeneity even more.

Possible mechanisms of action of IVIg in autoimmune and inflammatory diseases are: intact Fc-dependent blockage of IgG (as in ITP), inhibition of membrane attack complexes (C5b-C9) and activated components C3b and C4b (as in Kawasaki\'s disease), and anti-idiotypes against autoantibodies (as in acquired hemophilia due to autoantibodies against factor VIII). IVIg also contains various cytokines and natural antibodies that may act against pathogens, altered molecules, cells, autoreactive B cell clones, and tumors.

Methods {#Sec2}
=======

A panel of immunologists and internists with experience in IVIg therapy reviewed the medical literature indexed in PubMed using specific terms for each specific disease/condition AND ("IVIg" OR "IgIV" OR "Intravenous Immunoglobuli\*" OR "gamma globuli\*"). There was no limitation on language, year of publication, or publication status. We used all clinical data ranging from multicentered randomized controlled trials (RCT) and meta-analysis to case reports. From each article, we extracted details of the study design, number of patients, type of intervention including the dose and IVIg preparation used (if mentioned), and response to treatment. The relevant data were summarized in a hierarchical manner according to the study design and number of participants. When evidence was based on higher level of evidence studies, such as RCTs, lower levels of evidence studies (such as case control studies) were disregarded. Specific diseases were classified in tables according to the specialty they belong to and are followed by a short summary of recommendations, including the level of evidence and the strength of recommendation, as assessed by known guidelines (Table [1](#Tab1){ref-type="table"}) \[[@CR2]\]. To our knowledge, this is the first comprehensive review which summarizes all up-to-date published data regarding the usage of IVIg in autoimmune diseases, immune deficiencies, and other indications. Table 1Recommendation guidelines \[[@CR2]\]Level of evidence A: more than one randomized controlled trial (RCT)/meta-analysis B: a single RCT or well-designed nonrandomized trial like prospective observational registries (case--controls, cohorts). C: expert consensus: this includes case reports and retrospective series; here, the expert decides based on his experienceStrength of recommendationClass I: conditions for which there is evidence and/or general agreement that a given procedure/therapy is useful and effective Class II: conditions for which there is conflicting evidence and/or divergence of opinion about the usefulness/efficacy of performing the procedure/therapy Class IIa: weight of evidence/opinion is in favor of usefulness/efficacy Class IIb: usefulness/efficacy is less well established by evidence/opinion Class III: conditions for which there is evidence and/or general agreement that a procedure/therapy is not useful/effective and in some cases may be harmful

Results {#Sec3}
=======

The tables below summarize the clinical data gathered from studies dealing with IVIg treatment for different conditions. Each table is followed by our evidence-based recommendations for the usage of IVIg ( Table [2](#Tab2){ref-type="table"}). Table 2The use of intravenous immunoglobulins in rheumatologic diseasesDiseaseRef.Study designIntervention including dose and IVIg preparation usedNumber of patientsResults/responseSystemic lupus erythematosus (SLE) systemic flare-up\[[@CR36]\]Controlled trialIVIg 0.4 g/kg for 5 days, between 1 and 8 monthly courses (mean 5; ISIVEN-Instituto Sierovaccinogeno, Italiano ISI SpA.)20 patients with active SLEBeneficial clinical response in 17 out of 20 pts (*p* \< 0.0001); especially in arthritis, fever, thrombocytopenia, and CNS lupus\[[@CR37]\]Uncontrolled multicenter trialIVIg 0.4 g/kg for 5 days13 females with acute exacerbation of SLEAfter IVIg treatment, the modified European Consensus Lupus Activity Measurement (mECLAM) declined in 12 out of 13 pts by ≥3 points (*p* = 0.0002)\[[@CR38]\]Uncontrolled trial30 g of sulfonated IVIg preparation on days 1--4 and 21--2412 patients with mild-to-moderate active SLEWithin 6 weeks, the mean Systemic Lupus Activity Measure (SLAM) score declined from 7.3 to 5.25 (*p* \< 0.01); in a minority, this effect lasted 5--12 months\[[@CR19]\]Retrospective trialReview of medical records of patients with SLE that were treated with low-dose IVIg (0.5 g/kg) for several courses62 patientsClinical improvement in most disease manifestations including pericarditis; not including thrombocytopenia and alopeciaLupus myocarditis\[[@CR39]\]Case seriesIVIg 0.4 g/kg per day for 5 days, in addition to CP or MMF (given to 2 patients)3 patients with lupus myocarditis and severe deterioration in contractile functions; high-dose CS had little effectMarked clinical improvement; decreased need for CS\[[@CR40]\]Case reportIVIg 0.4 g/kg per day for 5 days1 patient with lupus myocarditis refractory to CSMarked improvement of severe cardiac dysfunction after one course of IVIgSLE and thrombocytopenia\[[@CR41]\]Retrospective trialIVIg 2 g/kg for 2 to 5 days31 patients with severe thrombocytopenia associated with SLE refractory to PD treatmentA transient response was observed in 20 patients (65%); no sustained response was observedSubacute cutaneous lupus erythematosus (SCLE)\[[@CR42]\]Case seriesIVIg with starting doses of 1 g/kg for 2 days, followed by 0.4 g/kg monthly, until disease resolution or for 6 months12 patients with resistant SCLE5 patients had complete or near-complete clearing of their skin disease; two had partial improvement and 3 had limited responses\[[@CR43]\]Case seriesIVIg 0.3 g/kg per day for 5 days each month for 12 months7 patients with skin disease (5 had systemic LE; two had SCLE)IVIg was unable to control cutaneous disease efficiently\[[@CR44]\]Case seriesIVIg3 patients with SCLE resistant to topical and systemic therapyGood response\[[@CR45]\]Case reportIVIg 2 g/kg monthly30-year-old woman with SCLEGood responseVarious manifestations of SLE\[[@CR46]\]Various case reportsDifferent IVIg preparations and doses26 patients with specific lupus manifestations refractory to standard Tx.: autoimmune hemolytic anemia (2), acquired factor VIII inhibitors (2), acquired von Willebrand disease (2), pure red cell aplasia(3), pancytopenia (1), myelofibrosis (1), pneumonitis (2), pleural effusion (1), pericarditis (2), myocarditis (2), CNS lupus (6), peripheral neuropathy (1), polyradiculoneuropathy (1)Improvement of SLE-related conditionFor lupus nephritis, see kidney sectionFor Kawasaki disease, see cardiology sectionKikuchi Disease\[[@CR47]\]Case reportIVIg 0.4 g/kg per day for 3 daysA 35-year-old patient with Kikuchi, refractory to steroids and thalidomideA definite improvement in her facial swelling occurred within 4 days, followed by gradual but complete resolution of lymphadenopathy over the subsequent 8 weeks, despite stopping steroid medication\[[@CR48]\]Case reportIVIg 1 g/kg per day for 2 days, plus PD (2 mg/kg per day)2 children who had Kikuchi complicated with hemophagocytic syndromeOne responded dramatically; second case responded partially to IVIg and fully after PD was addedStill's disease\[[@CR49]\]Uncontrolled trialPatients received monthly IVIg7 patients unresponsive or poorly responsive to nonsteroidal anti-inflammatory drugs5 patients responded after 4--6 treatments; 2 failed to respond\[[@CR50]\]Uncontrolled trialBetween 1 and 8 IVIg monthly infusions with a dose of 1 g/kg per day for 2 days7 patients suffering from adult Still\'s diseaseAll patients improved but relapsed after 3--24 months\[[@CR51]\]Case report2 courses of IVIg 1 g/kg for 2 days23-year-old patient with flare-up of disease while taking salicylates at gestational week 22Significant clinical and laboratory improvementGranulomatous arteritis (GA, Wegener\'s granulomatosis)\[[@CR52]\]Multicentered RCT14 patients received IVIg 2 g/kg in 5 days (sandoglobulin Novartis) vs. 14 placebo34 patients with ANCA-associated vasculitis (GA or MPA), refractory to CS or CPReduction in Birmingham Vasculitis Activity Score of 50% in 14/17 and 6/17 of the IVIg and placebo groups, respectively\[[@CR53]\]Uncontrolled trialPatients received IVIg (Sandoglobulin)14 patients with GA who responded poorly to standard therapyAll patients were in full and partial remission after 8 weeks; clinical benefit was maintained a year later\[[@CR54]\]Uncontrolled trialSingle or multiple courses of IVIg, 30 g/day, over 5 days15 patients with GA who responded poorly to standard therapy40% of patients benefited from IVIg treatment but without complete remission\[[@CR55]\]Uncontrolled trialMonthly IVIg, 0.4 g/kg for 5 days, 1--6 cycles (Isiven Instituto Sierovaccinogeno, Italiano ISI SpA.)10 patients with GA, CSS, or undifferentiated vasculitis which were refractory to standard treatmentIVIg treatment was found beneficial in 6 out of the 10 patients\[[@CR56]\]Uncontrolled trialIVIg 0.5 g/kg per day for 4 days; Sandoglobulin (Sandoz, Basel, Switzerland)3 patients with GA not treated with immunosuppressants beforeOne patient had full remission; one had transitional response; one had no responseMicroscopic polyangitis (MPA)\[[@CR57]\]Uncontrolled trialIVIg 0.4 g/kg per day for 5 days, before or along with CS or CP (kenketsu velilon-I, Teijin Co., Ltd., Tokyo or kenketsu Glovenon-I, Nihon pharmaceutical Co., Ltd., Tokyo, Japan)30 patients with MPA plus rapidly progressive glomerulonephritisAt 6 months, renal and general survival were 92% and 93%, respectively, compared to 70% and 74% with conventional therapy in other studies\[[@CR56]\]Uncontrolled trialIVIg 0.5 g/kg per day for 4 days (Sandoglobulin, Sandoz, Basel, Switzerland)3 patients with MPA not treated with immunosuppressants beforeOne patient had full remission; one had transitional response; one had no response\[[@CR53]\]Uncontrolled trialPatients received IVIg (Sandoglobulin)11 patients with MPA who responded poorly to standard therapy8 weeks after IVIg, all patients were in full and partial remission, clinical benefit was maintained 12 months later in most patientsChurg--Strauss syndrome (CSS)\[[@CR58]\]Controlled trialAll patients received PS and CP in severe cases; 9 received monthly PP, followed by IVIg 1 g/kg for 2 days (Ig vena N IVH; Sclavo, Siena, Italy)18 patients with CSSAfter 12 months, all patients in the IVIg group and 4 (44%) in the control group were in remission; a significant favorable outcome was kept after 3 years (*p* \< 0.01)\[[@CR59]\]Case seriesDaily IVIg 0.4 g/kg for 5 days5 patients with cardiac CSS who showed poor response to PS ± CPNeuropathy improved; EF of patients improved from 35.2% to 61% (*p* \< 0.02)\[[@CR55]\]Case report5--6 courses of monthly IVIg, each course 0.4 g/kg for 5 days (Isiven Instituto Sierovaccinogeno, Italiano ISI SpA.)2 patients with CSS, nonresponsive to standard treatmentFirst patient had no improvement; second patient had clinical and laboratory improvement and was steroid-sparedAutoimmune hepatitis (AIH)\[[@CR60]\]Case reportIVIg was initiated because of adverse affects of long-term steroid therapyA patient with chronic AIHImmediate clinical, serological, and histological improvementAutoimmune features in hepatitis C virus (HCV) infection\[[@CR61]\]RCTIVIg 0.4 g/kg for 5 days, and then IFN alpha 3 times a week, compared to treatment with IFN alpha alone42 patients with HCV and autoimmune phenomenaA higher percentage of patients who received IFN alpha plus IVIg showed complete virological and histological responsesHenoch--Schönlein purpura (HSP)\[[@CR62]\]Cohort studyIVIg 1 g/kg for 2 days, every month for 3 months (Biotransfusion, Roissy, France)11 adult patients with severe IgA nephropathy (9 idiopathic, 2 with HSP)Substantial improvement in glomerular filtration rate and kidney functions; 2 patients with HSP had resolution of other systemic symptoms\[[@CR63]\]Case reportIVIg (Tegelines) 1 g/kg per day for 2 daysA 10-year-old boy with HSP and severe abdominal manifestations refractory to treatment with CSDigestive symptoms disappeared within 3 days\[[@CR64]\]Case reportPatient was treated with IVIgA 26-year-old woman with HSP with nephrotic syndrome refractory to CSDramatic resolution\[[@CR65]\]Case reportIVIg (polyglobulin N containing maltose) 0.4 g/kg, for 2 days46-year-old man with HSP and MPGNDeveloped hemolysis and rapid deterioration renal function\[[@CR66]\]Case reportIVIg 1 g/kg for 2 days56-year-old man with HSP and severe digestive manifestationsThe patient\'s purpura and abdominal syndrome improved dramaticallyMixed connective tissue disease (MCTD)\[[@CR67]\]Case reportIVIg 0.4 g/kg for 5 daysA woman with MCTD and fasciitisQuick improvement of her symptoms and decreased CRP\[[@CR68]\]Case reportPatient was treated with IVIgA 69-year-old man with MCTD and nonresponsive skin eruptionsSuccessful control of diseaseSystemic sclerosis (SSc)\[[@CR69]\]Controlled trialIVIg 0.4 g/kg daily for 5 days, monthly for 3--6 cycles15 patients with SScTreatment resulted in significant improvement in quality of life (*p* = 0.03) and a decrease in Rodnan skin score (*p* \< 0.001)\[[@CR70]\]Case seriesIVIg 0.4 g/kg daily for 5 days5 patients with diffuse SScMarked long-term improvement in skin thickness from 2 weeks of treatment (*p* \< 0.01)\[[@CR71]\]Controlled trialMonthly IVIg 0.4 g/kg for 4 days, for 6 months7 female patients with SSc (5 limited, 2 diffuse), with a severe refractory joint involvementSignificant improvement in joint swelling and pain (*p* \< 0.03), as well as skin score (*p* \< 0.003), after 6 months of therapy\[[@CR72]\]Case report3--6 cycles of IVIg 0.4 g/kg for 5 days; ISIVEN (Instituto Sierovaccinogeno, Italiano ISI SpA, Italy)3 patients with rapid deteriorating SSc refractory to treatmentAll patients had a significant decrease in their skin scoreFor scleromyxedema, see dermatology sectionFor Evan\'s syndrome, see hematology sectionJuvenile rheumatoid arthritis (JRA)\[[@CR73]\]Multicentered RCTBimonthly IVIg 1.5--2.0 g/kg for the first 2 months, then monthly for up to 6 months (Iveegam, Immuno AG, Vienna) after 3 and a half months was switched to placebo25 patients with resistant JRA19 (76%) had moderate to large improvement; the group which switched to placebo showed rapid loss of this effect\[[@CR74]\]RCTPatients were additionally treated with high-dose IVIg or MP20 patients with JRA treated with MTX and CSClinical effects were rapid in both groups\[[@CR75]\]Retrospective cohortIVIg monthly for 3--54 months27 patients with systemic JRA20 patients responded after 6 months, especially systemic features and CS dependence\[[@CR76]\]Controlled trialHigh-dose IVIg16 children with severe juvenile chronic arthritisMild--moderate systemic, articular and laboratory improvement in most patientsRheumatoid arthritis (RA)\[[@CR77]\]RCTIVIg 5 g/kg every 3 weeks for 6 courses vs albumin20 patients with refractory RANo significant differences between treatment groups were noted during the 18-week trial\[[@CR78]\]Controlled trialPatients were treated with IVIg11 patients with refractory RAIn 6 patients, clinical results were impressive; lasting responses could be achieved in 3 patients only\[[@CR79]\]Case reportIVIg 1 g per day for 2 days, monthly for 3 months4 patients with severe refractory RA who have failed at least 4 second-line drugsNone of the patients improved or worsened\[[@CR80]\]Case reportIVIg 0.4 g/kg for 5 daysA 50-year-old woman with acute systemic RA refractory to treatment with CS, CP, or PPClinical improvement 3 days after IVIg treatmentSjögren\'s disease\[[@CR81]\]Case series3 monthly courses of IVIg 0.4 g/kg body for 5 days5 Sjögren patients complicated with ataxic sensory neuropathy, refractory to CS or PP4 patients showed remarkable improvement, 2 of whom responded after the first course\[[@CR82]\]Case reportIVIg 0.4 g/kg for 5 daysA patient with long-standing Sjögren\'s that developed a painful sensory neuropathyRemarkable clinical improvement and reduction of pain\[[@CR83]\]Case reportIVIg 0.4 g/kg for 5 days every 3 weeksA patient with Sjögren syndrome complicated with ataxic sensory neuropathyRemarkable improvement that subsided after switching to CS but regained after reintroduction to IVIg despite withdrawal of CSFor antiphospholipid syndrome, see gyneco-obstetric sectionPolymyositis (PM) and dermatomyositis (DM)\[[@CR84]\]RCTReceived PD 25 mg plus IVIg 2 g/kg or placebo every month for 3 months15 patients with treatment-resistant DMSignificant improvement of muscle strength (*p* \< 0.018) and neuromuscular symptoms (*p* \< 0.035), with IVIg treatment compared to placebo\[[@CR85]\]Controlled trialIVIg or standard therapy16 patients with PM or DMClinical and functional remission in a higher percentage (81%) that was maintained after a mean 5-year follow-up period, as compared to control group (*p* \< 0.001)\[[@CR86]\]Controlled trialIVIg 0.4 g/kg per day for 5 days in addition to CS (Benesis Corporation, Osaka, Japan).15 patients with Dm (7) or PM (8), who were refractory to traditional CS therapySignificant improvement in muscle strength, daily activity scores with no severe adverse reactionsInclusion Body myositis (IBM)\[[@CR87]\]RCTRandomized to receive IVIg or placebo monthly for 3 months36 patients with IBM, treated with high dose PDNo clinical significant difference\[[@CR88]\]RCTIVIg 2 g/kg Vs placebo22 patients with sporadic inclusion body myositisNo significant changes between groups according to modified Medical Research Council (MRC) score; mild improvement with IVIg according to Neuromuscular Symptom Score (NSS)\[[@CR89]\]RCTIVIg 2 g/kg vs placebo monthly for 3 months19 patients with IBMNo significant changes between the groups according to MRC score; significant improvement in swallowing with IVIg (*p* \< 0.05)Behcet\'s disease (BD)\[[@CR90]\]Case series0.4 g/kg daily of IVIg (Omr-*IgG*-am, a 5% solution of human normal immunoglobulin G; Omrix Biopharmaceuticals Ltd, Nes-Ziona, Israel) 5 times in the first week, an additional 3 applications in the first month, once every 20 days for the next 3 months, then every 6 weeks for 1 year6 eyes of 4 patients with ocular BD refractory to CS and cyclosporin AAll 6 eyes of all 4 patients showed good response to IVIg therapy\[[@CR91]\]Case reportIVIg was started with 5 daily doses of 0.4 g/kg followed by reinforcement doses of 0.4 g/kg at 2-week intervalsA 28-year-old man with BD suffering from severe leg, mouth, and scrotal ulcers and phlebitis resistant to immunosuppressantsAfter 4 days, the ulcers started to heal; 2 months later, the patient became totally pain free and walked without limping

SLE---systemic flare-up {#Sec4}
-----------------------

### Level of evidence B {#d29e1891}

Systemic lupus erythematosus (SLE) is a multisystemic disease with various manifestations. There is some evidence that IVIg, given in patients without an increased risk for thromboembolic events or renal failure, is a safe and beneficial adjunct therapy for SLE patients with systemic flare-ups who are resistant to or refuse conventional treatment (*strength of recommendation I*).

Lupus myocarditis {#Sec5}
-----------------

### Level of evidence C {#d29e1902}

Lupus myocarditis is an uncommon but severe complication of SLE. There is no consensus on the specific treatment of SLE myocarditis. Most reports describe treatment with high-dose corticosteroids (CS), followed by either cyclophosphamide or azathioprine, in addition to conventional treatment for heart failure. There is little evidence that IVIg is effective when immunosuppressive therapy fails (*strength of recommendation II*).

SLE and thrombocytopenia {#Sec6}
------------------------

### Level of evidence B {#d29e1913}

As with the treatment of ITP, IVIg seems to be useful in managing the bleeding complications of patients with lupus-associated thrombocytopenia (*strength of recommendation I*).

Subacute cutaneous lupus erythematosus {#Sec7}
--------------------------------------

### Level of evidence C {#d29e1924}

Standard therapy for subacute cutaneous lupus erythematosus (SCLE) includes CS (topical, intralesional, systemic), antimalarials, and other immunosuppressive agents**.** IVIg may be considered in refractory cases, but more study should be done (*strength of recommendation IIa*).

### Level of evidence C {#d29e1935}

Kikuchi, also called histiocytic necrotizing lymphadenitis, is a rare benign disease. There is little evidence that treatment with IVIg is superior to other anti-inflammatory treatments (*strength of recommendation IIa*).

Adult still disease {#Sec8}
-------------------

### Level of recommendation C {#d29e1946}

Giving the fact that adult still disease responds to CS and biological and anti-tumor necrosis factor (TNF) treatment, there is low-level evidence that IVIg has an additional benefit for treatment of this disease (*strength of recommendation IIa*).

Systemic vasculitis (including GA and MPA) {#Sec9}
------------------------------------------

### Level of recommendation B {#d29e1957}

Immunosuppression with CSs and cytotoxic agents should be used in systemic vasculitis before considering IVIg. There is however some evidence that IVIg might be useful and therefore in refractory cases it may be worth to try (*strength of recommendation IIa*).

Churg--Strauss syndrome {#Sec10}
-----------------------

### Level of evidence B {#d29e1968}

CSS is a rare disease. The initial management of CSS consists of high doses of CS. For patients with severe disease or those who are unresponsive to CS, treatment with IVIg was warranted (*strength of recommendation IIa*).

Hepatitis C virus with autoimmune features {#Sec11}
------------------------------------------

### Level of evidence B {#d29e1979}

Infection with hepatitis C virus (HCV) may be associated with a variety of autoimmune phenomena causing a therapeutic dilemma for treatment with interferon alpha (IFN alpha), which stimulates autoimmune symptoms, or with CS, which may lead to an increase of viral load. Treatment with IVIg may act synergistically with IFN alpha, achieving a better response to IFN treatment in patients with chronic HCV associated with autoimmunity (*strength of recommendation IIa*).

Henoch--Schönlein purpura/IgA nephropathy {#Sec12}
-----------------------------------------

### Level of evidence B {#d29e1990}

There is some evidence that IVIg treatment may be effective for systemic and kidney disease, rather without sucrose/mannose in the preparation (*strength of recommendation I*).

Mixed connective tissue disease {#Sec13}
-------------------------------

### Level of evidence C {#d29e2002}

Mixed connective tissue disease (MCTD) is an autoimmune condition which combines features of polymyositis, systemic lupus erythematosus, scleroderma, and dermatomyositis and is thus considered an overlap syndrome. There is scarce evidence that treatment with IVIg helps to improve skin manifestations in MCTD (*strength of recommendation IIa*).

Systemic sclerosis {#Sec14}
------------------

### Level of evidence B {#d29e2013}

Systemic sclerosis is characterized by hardening and scarring of the skin and inner organs. There is some evidence that treatment with IVIg helps to improve skin and systemic symptoms (*strength of recommendation I*).

Juvenile rheumatoid arthritis {#Sec15}
-----------------------------

### Level of evidence A {#d29e2024}

There is evidence that IVIg is useful for the treatment of patients with severe chronic JRA; its treatment may help also reduce the need for CS and other immunosuppressive therapy (*strength of recommendation I*).

Rheumatoid arthritis {#Sec16}
--------------------

### Level of evidence B {#d29e2035}

There is hardly any convincing evidence that IVIg benefits patients with RA (*strength of recommendation IIb*).

Sjögren\'s disease {#Sec17}
------------------

### Level of evidence C {#d29e2046}

There is some evidence that patients with ataxic sensory neuropathy refractory to immunosuppressive therapy will benefit from IVIg (*strength of recommendation IIa*).

Myopathies (PM, DM, and IBM) {#Sec18}
----------------------------

### Level of evidence B {#d29e2057}

In patients with DM and PM that are resistant or partially responsive to conventional therapies, IVIg was effective (*strength of recommendation I*).

### Level of evidence A {#d29e2065}

In IBM, IVIg showed marginal improvements in muscle strength which were nonsignificant and thus were not recommended (*strength of recommendation III*).

Behcet\'s disease {#Sec19}
-----------------

### Level of evidence C {#d29e2076}

Behcet\'s disease is a multisystemic disorder presenting with recurrent oral and genital ulcers as well as ocular and central nervous system involvement. The severe cases may respond to systemic CSs, interferon, or anti-TNF therapy. There is some evidence to support IVIg treatment for refractory eye and skin involvement (*strength of recommendation I*; Table [3](#Tab3){ref-type="table"}). Table 3The use of intravenous immunoglobulins in hematological diseasesDiseaseRef.Study designIntervention including dose and IVIg preparation usedNumber of patientsResults/responseAcquired hemophilia\[[@CR92]\]Prospective multicenter studyInduction with IVIg (5% Gamimune-N, Miles Inc, Berkeley, CA, USA) 2 g/kg over 2 or 5 days, maintenance with 0.4 g/kg by clinician decision19 patients with acquired factor VIII inhibitors8 of 16 assessable patients (50%) had inhibitors reduced in more than 25%; in one third of these responses, concomitant CS treatment may have influenced results\[[@CR93]\]Review of published case reportsDifferent IVIg preparations, dose ranging from 1.6 to 2.8 g/kg over 2--7 days26 patients with acquired factor VIII inhibitors16 of 26 patients (62%) had inhibitors reduced in more than 25%; 7 of 26 patients (27%) had clinical benefit\[[@CR93]\]Case seriesIVIg (Sandoglobulin) 2 g/kg over 5 days4 patients with acquired factor VIII inhibitors2 of 4 patients (50%) had inhibitors reduced in more than 25%, but with no clinical benefit; in 2 of 4 patients, the inhibitor reductions were no assessable due to concomitant CS or CP treatment, with clinical benefit in doubt\[[@CR94]\]Review of published case reportsDifferent IVIg preparations and doses; IVIg therapy alone35 patients with acquired factor VIII inhibitors30% had inhibitors reduced in more than 25% and clinical benefit\[[@CR95]\]Case seriesPrednisolone 1 mg/kg per day with IVIg 2 g/kg over 2--5 days7 patients with acquired factor VIII inhibitors5 of 7 patients (71%) had inhibitors reduced in more than 25%Acquired hypogammaglobulinemia\[[@CR96]\]RCT crossover study6 months IVIg (0.3 g/kg per month, Ig-Vena N, Sclavo, Siena, Italy) or placebo, then switch for 12 months and switch again for 6 months42 CLL patients with hypogammaglobulinemiaIVIg treatment yielded more infection free patients at 6 months than placebo (20 vs. 9, *p* \< 0.01) as well as at 12 months (13 vs. 6, *p* \< 0.02)\[[@CR97]\]RCT crossover study12 months IVIg 0.4 g/kg (Gammagard, Hyland Therapeutic Division, Baxter Healthcare, Glenoak, CA, USA) every 3 weeks or placebo, then switch for 12 months12 B cell CLL or NHL patients with hypogammaglobulinemiaDuring IVIg treatment, there were more infection-free patients than during placebo administration (6 vs. 1, *p* = 0.001); in addition, 10 of 12 had lower rates of severe bacterial infection while on IVIg (*p* = 0.001)\[[@CR98]\]RCT18 g IVIg or albumin each 3 weeks for 12 months42 CLL patients with hypogammaglobulinemiaFewer infections in IVIg-treated (29% vs. 61%, *p* = 0.04)Fewer severe infections in IVIg-treated (21% vs. 56%, *p* = 0.02)\[[@CR99]\]RCTIVIg 0.4 g/kg (Gammagard, Baxter Healthcare) or albumin every month for 12 months82 patients with multiple myeloma19 serious infection in IVIg-treated compared with 38 in placebo-treated patients (*p* = 0.019)No septicemia/pneumonia on IVIg treatment compared with 10 cases in placebo-treated (*p* = 0.002)\[[@CR100]\]RCTIVIg (Endobulin, Immuno) 0.4 g/kg or no treatment each month, for 6 months60 children with acute lymphoblastic leukemiaLess infections in IVIg-treated patients\[[@CR101]\]RCTCefataxim and amikacin with or without IVIg33 children with acute lymphoblastic leukemia and neutropenic feverShorter fever duration in IVIg group (5.2 vs. 7.9 days, *p* \< 0.05)Similar neutropenia and hospitalization duration\[[@CR102]\]RCTIVIg (Gammagard Baxter Healthcare Corporation Hyland Division) 0.4 g/kg or placebo every 3 weeks for 12 months84 CLL patients with hypogammaglobulinemia or a history of infectionOverall fewer bacterial infections in the IVIg group (23 vs. 42, *p* = 0.01)Even more marked difference in those who completed 1 year (14 vs. 36, *p* = 0.001)\[[@CR103]\]RCT crossover study6 months IVIg 0.3 g/kg per month (Ig-Vena N, Sclavo, Siena, Italy) or no therapy, then switch for 12 months and switch again for 6 months25 multiple myeloma patients with hypogammaglobulinemiaDuring IVIg treatment, ten serious infections occurred; during no therapy, phase 30 serious infections occurred, *p* \< 0.002\[[@CR104]\]Two trials: RCT and RCT crossover study12 months IVIg 0.4 g/kg every 3 weeks (Gammagard Baxter Healthcare Corporation Hyland Division) or placebo, then switch for 12 months (only in the case of the RCT crossover trial)RCT trial: 81 patients with B cell CLL or low-grade NHL patients with hypogammaglobulinemiaRCT trial: less bacterial infections in the IVIg group (23 vs 42, *p* = 0.01)RCT crossover study: 12 patients with B cell CLL or low-grade NHL patients with hypogammaglobulinemiaRCT crossover trial: larger number of patients free of severe infections in the IVIg group (6 vs 1, *p* = 0.001)Pure red cell aplasia\[[@CR105]\]Case seriesIVIg 2 g/kg over 5 days3 pure red cell aplasia patientsGood response in all patients\[[@CR106]\]Case seriesIVIg 2 g/kg (2 patients received Sandoglobulin, Sandoz, Switzerland, 2 patients received Veinoglobulin, Institut Merieux, France) over 5 days4 patients with red cell aplasia, one idiopathic, another with well-differentiated lymphoma and 2 with B cell CLLGood response in all patients\[[@CR107]\]Case reportIVIg42-year-old male with parvovirus-B19-induced red cell aplasia after stem cell transplantationGood response\[[@CR108]\]Case reportIVIg 2 g/kg over 5 days38 year-old male with parvovirus-B19-induced red cell aplasia after liver transplantationGood response\[[@CR109]\]Case reportIVIg (Panglobulin, ZLB Bioplasma, AG, Bern, Switzerland) 2 g/kg over 2 days14-year-old male with parvovirus-B19-induced red cell aplasia after renal transplantationGood response but development of osmotic sucrose-related renal failure\[[@CR110]\]Case reportIVIg 1 g/kg single dose26-year-old female with parvovirus-B19-induced red cell aplasia after CHOP chemotherapy, rituximab, and radiotherapyGood response\[[@CR111]\]Case reportIVIgRelapsing pure red cell aplasia in a patient with B-cell chronic lymphocytic leukemia, refractory to PD and CPGood response\[[@CR112]\]Case reportIVIg 4 g/kg over 10 daysPatient with parvovirus-B19-induced red cell aplasia after renal transplantationGood response\[[@CR113]\]Case reportIVIg41-year-old male patient with acquired immunodeficiency syndrome and parvovirus-B19-induced red cell aplasiaGood response\[[@CR114]\]Case seriesIVIg 1 to 2 g/kg over 1 to 2 days + maintenance dose 0.4 g/kg each month8 patients with acquired immunodeficiency syndrome and parvovirus-B19-induced red cell aplasiaGood response in 8 of 8 patients, 6 of 8 needed also maintenance IVIg\[[@CR115]\]Case report0.3 g/kg IVIg (Venilon, Teijin, Osaka) over 6 days28-year-old female patient with common variable immunodeficiency and parvovirus-B19-induced red cell aplasiaGood response\[[@CR116]\]Case report1 g/kg IVIg34-year-old male with acquired immunodeficiency syndrome and parvovirus-B19-induced red cell aplasiaGood response\[[@CR117]\]Case report2 g/kg IVIg (Intragam, CSL) over 5 daysMale patient with acquired immunodeficiency syndrome and parvovirus-B19-induced red cell aplasiaGood response\[[@CR118]\]Case report2 g/kg IVIg then variable maintenance doses26-year-old male patient with acquired immunodeficiency syndrome and parvovirus-B19-induced red cell aplasiaGood response\[[@CR119]\]Case reportIVIgFemale patient with chronic idiopathic pure red cell aplasiaGood response including 2 uneventful pregnancies during treatment\[[@CR120]\]Case report2 g/kg IVIg over 5 days22-year-old female patient with systemic erythematosus lupus and pure red cell aplasia, after failure of CS therapyGood and immediate response\[[@CR121]\]Case report4 g/kg IVIg (Sandoglobulin) over 10 days, subsequent additional shorter courses and plasmapheresis to due to immune-complex disease24-year-old female patient with parvovirus-B19-induced red cell aplasia after liver transplantationLate response; it is questionable that the late response is due to IVIg due to the late timing\[[@CR122]\]Case report2 g/kg IVIg (Sandoglobulin, Sandoz, East Hanover, NJ, USA) over 5 days, subsequent maintenance courses4-year-old patient pure red cell aplasiaGood and long-term response, weaned of blood transfusions\[[@CR123]\]Case report2 g/kg IVIg over 5 days, subsequent maintenance courses65-year-old Waldenström\'s macroglobulinemia patient with parvovirus-B19-induced pure red cell aplasiaGood and long-term response, weaned of blood transfusionsAcquired von Willebrand syndrome\[[@CR7]\]Prospective noncontrolled study with sequential treatmentsDesmopressin and factor VIII/von Willebrand factor concentrate where compared to IVIg 2 g/kg over 2 days (Sandoglobulin, Novartis or Ig-Vena Sclavo)10 MGUS patients with acquired von Willebrand syndrome: 8 had IgG-kappa or lambda, 2 had IgM-kappaTransient increase in plasma von Willebrand factor with desmopressin and factor VIII/von Willebrand factor concentrate; IVIg infusion in IgG-MGUS resulted in a more sustained increase starting on day 4 and returning to preinfusion levels on day 21\[[@CR94]\]Case seriesIVIg9 acquired von Willebrand syndrome patientsGood response in 30%\[[@CR124]\]Case reportIVIg 0.9 g/kg over 3 days43-year-old patient with multiple myeloma and gastrointestinal bleeding due to acquired von Willebrand syndrome not responsive to vasopressinRapid hematological correction after 4 days, bleeding control\[[@CR125]\]Case reportIVIg2 SLE patients with von Willebrand syndromeGood response in one of the 2 patientsAplastic anemia\[[@CR1]\]Case reportIVIg2 patients with idiopathic aplastic anemiaNo response\[[@CR126]\]Case reportIVIgAplastic anemia patient unresponsive to antithymocyte globulin and CSGood response\[[@CR127]\]Case reportIVIgAplastic anemia due to parvovirus B19 infection in a heart transplant recipientGood response\[[@CR128]\]Case reportIVIg (ISIVEN, Instituto Sierovaccinogeno, Italiano ISI SpA) 2 g/kg over 5 days66-year-old woman with idiopathic aplastic anemia, unresponsive to CSGood responseAutoimmune hemolytic anemia\[[@CR129]\]Multicenter noncontrolled study + review of reported casesIVIg (generally Sandoglobulin, Basel, Switzerland, but also Gamimmune N, Cutter Biological, Emeryville, CA, USA; Venilon, Teijin Institute, Tokyo; Sanglopor, Sankyo Institute, Tokyo) 2.5--7 g/kg over 5--7 days73 patients with autoimmune hemolytic anemia: 36 from multicenter study, 37 from review of published cases29 patients (39.7%) responded to IVIg: hepatomegaly and low pretreatment hemoglobin were correlated with good responseAutoimmune neutropenia\[[@CR130]\]Case seriesIVIg 0.4--1 g/kg for 5--3 days20 infants with neutropenia50% responded after IVIg as compared to 100% with G-CSF and 57% with CS\[[@CR131]\]Case seriesIVIg 3 g/kg over 3 days6 infants with neutropeniaFast but transient rise in neutrophils in allEvans\' Syndrome\[[@CR132]\]Case seriesIVIg single or multiple courses + CS40 patients (children and young adults)Remission in 9/40, transient response in 26/40 (overall improvement in 87%)\[[@CR133]\]Case seriesIVIg plus CS for either acute hemolysis or thrombocytopenia5 pediatric patientsTransient effect that needed immunosuppressant therapy for maintenance\[[@CR134]\]Case reportIVIg 0.4 g/kg for 5 days3 patients with ES refractory to conventional therapy, including CS and splenectomy in all of the patients, vincristine in 2, and CP in one2 patients failed to respond, but the third had a clinical remission after IVIg therapy\[[@CR135]\]Case reportIVIg 0.4 g/kg for 5 daysA patient with steroid resistant ES associated with dermatomyositisIVIg was transiently effective, but a sustain remission was achieved with CPFetal/neonatal alloimmune thrombocytopenia\[[@CR136]\]Nonrandomized studyIVIg, 1 g/kg weekly, or CS given to pregnant women37 pregnant women with previous pregnancy with alloimmune thrombocytopenia: 27 received IVIg, 10 received CSThere was an increase in platelets and no intracranial bleeding in 26% of patients/fetus treated with IVIg as compared with 10% of those treated with CS; in addition, there was no increase in platelets and no intracranial bleeding in 41% of patients/fetus treated with IVIg as compared with 20% of those treated with CSStem cell/bone marrow transplantation: infections and graft-versus-host disease\[[@CR137]\]RCT16 weekly doses since 1 week before transplantation of either IVIg (Sandoglobulin, Novartis Pharma, Rueil-Malmaison) 0.05, 0.25, and 0.5 g/kg or placebo200 patients with allogeneic stem cell transplantationNo protection against infections; GVHD and mortality were similar\[[@CR138]\]Randomized trial64 patients received 0.4 g/kg per week of IVIg (Sandoglobulin, Sandoz, Switzerland); 64 patients received 0.1 g/kg per week of CMV-IgG128 patients with allogeneic bone marrow transplantationNo significant difference in the occurrence or severity of acute or chronic GVHD, infections, or survival\[[@CR139]\]RCT123 patients received 0.5 g/kg per month of IVIg; 127 patients did not receive IVIg, from the fourth to the 12th month after transplantation250 patients with allogeneic bone marrow transplantationNo significant difference in the occurrence of chronic GVHD, infections, or survival\[[@CR140]\]Randomized trialAll received CMV-negative blood products, 25 received IVIg (1 g/kg per week) starting before pretransplant conditioning and then for 17 additional weeks48 patients after allogeneic BMT, CMV seronegative, which received CMV seropositive or seronegative BMTNo difference in the number of bacterial/fungal infections, fewer non-CMV viral infections in the IVIg group (9 vs 15, *p* = 0.03), less grade ≥II of GVHD in the IVIg group, *p* = 0.04\[[@CR141]\]Multicenter RCTIVIg (Venoglobulin S 5%, Alpha Therapeutic Corporation, LA, CA, USA), 0.1, 0.25, or 0.5 g/kg, started 2 days before transplant, continued weekly for 90 days and then monthly until 1 year after transplant618 allogeneic bone marrow transplant recipientsAcute GVHD occurred in 39% (80/206) in the 0.1-g/kg group, 42% (88/208) in the 0.25-g/kg group, 35% (72/204) in the 0.5 g/kg groupNo difference in incidence of chronic GVHD, infection, interstitial pneumonia, type of infection, relapse of hematological malignancy or survival\[[@CR142]\]Randomized trialIVIg (Sandoglobulin, Sandoz Pharmaceuticals, East Hanover, NJ, USA) 0.5 g/kg per week administered since the beginning of the cytotoxic therapy or nothing170 autologous bone marrow transplant patientsIVIg did not reduce infection of infection-related death\[[@CR143]\]RCTIVIg (Gamimune N, Cutter Biological, Berkeley, CA, USA) 0.5 g/kg per week to day 90, then 0.5 g/kg per month to day 360 after transplantation or nothing382 patients after bone marrow transplantationLower risk of gram-negative septicemia (*p* = 0.0039) in IVIg and of local infection (*p* = 0.029)No difference in survival; there was a risk reduction in the incidence of acute GVHD (*p* = 0.0051)Decrease in deaths due to transplant-related causes after transplantation of HLA-identical marrow (*p* = 0.023)Hemolytic disease of the newborn\[[@CR144]\]Meta-analysis of 3 not-blinded RCTIVIg and phototherapy or phototherapy alone189 patientsLess use of exchange transfusion in the IVIg group: when given for prophylaxis RR = 0.21 (*p* \< 0.001), when given as treatment RR = 0.36 (*p* \< 0.006)\[[@CR145]\]Meta-analysis of 3 RCTsIVIg and phototherapy or phototherapy alone189 patientsOverall less use of exchange transfusion in the IVIg group: RR = 0.28 (*p* \< 0.00001)Hemolytic transfusion reaction\[[@CR146]\]Case seriesIVIg (Endobulin HT, Immuno AG, Vienna, Austria) 0.4 g/kg (single infusion) was administered within 24 h of transfusion5 patients are known to develop non-ABO post-transfusional hemolytic reactionsNo transfusion reaction and sustained increase in hematocrit\[[@CR147]\]Case reportIVIg (Sandoglobulin) 75 gr. over 3 days + CSRh-negative patient with anti-Jk, anti-K, and anti-KpIncrease in hemoglobin, no evidence for hemolysisHemolytic transfusion reaction in sickle cell disease\[[@CR148]\]Case reportsIVIg 2 g/kg over 5 days + high-dose MP2 patients with sickle cell disease who developed a hemolytic reaction after compatible blood transfusionIncrease in hemoglobin and reticulocytes\[[@CR149]\]Case reportsIVIg 2 g/kg over 5 days + high-dose MP2 patients with sickle cell disease who developed a hemolytic reaction after compatible blood transfusionIncrease in hemoglobin and reticulocytes\[[@CR150]\]Case reportIVIg (Sandoglobulin, 1 g/kg per day for 1 to 2 days) + CSPatient with sickle cell disease who developed a hemolytic reaction after compatible blood transfusionIncrease in hemoglobin and reticulocytesHemolytic uremic syndrome\[[@CR151]\]Case control studyIVIg 0.4--2.4 g/kg (Gamimune N, Cutter Etobicoke, Ontario, Canada) over 1--6 days (0.4 g/kg per day)18 children with postdiarrhea hemolytic uremic syndrome, 9 received IVIgNo benefit of IVIg treatment\[[@CR152]\]Case control studyIVIg 2 g/kg (Sandoglobulin) over 5 days in 8 patients, FFP in 12 patients, no treatment in 23 patients43 children with hemolytic uremic syndrome; 8 received IVIgImprovement in platelet count against FFP (*p* \< 0.05) and against no treatment (*p* \< 0.01)Thrombotic thrombocytopenic purpura\[[@CR153]\]Case seriesIVIg 0.4 g/kg per day, from 1 to 20 infusions; these patients were also treated with CS, also PP in 15 patients17 patients with thrombotic thrombocytopenic purpura10/17 (58.8%) patients had remission, 8/17 (47%) complete remission\[[@CR154]\]Case control studyIVIg 2 g/kg over 5 days in 29 patients only; all the patients received PP and CS44 patients with thrombotic thrombocytopenic purpuraNo benefit of IVIg treatmentHeparin-induced thrombocytopenia\[[@CR155]\]Case seriesIVIg (Sandoglobulin in 2 cases, Octagam in one case) 2 g/kg over 2 days3 patients with heparin-induced thrombocytopeniaIncrease in platelet count\[[@CR156]\]Case reportIVIg51-year-old woman with heparin-induced thrombocytopenia and pulmonary embolismIncrease in platelet count starting 20 h after first IVIg infusionHIV-associated thrombocytopenia\[[@CR157]\]RCT crossover studyWeekly IVIg (Polygam) courses of 2 g/kg over 2 days or normal saline, for 4 weeks, then crossover12 HIV patients with HIV-related thrombocytopeniaIVIg consistently and reproducibly raised platelet count after infusion; no patient with placebo did so (*p* \< 0.00003)Acute immune thrombocytopenic purpura\[[@CR158]\]RCT not blindedIVIg 2.1 g/kg over 3 days (Gammagard SD, Baxter Bioscience, Glendale, CA) or high-dose MP 15 mg/kg per day for 3 daysAcute immune thrombocytopenic purpura adult patients, 56 randomized to IVIg, 60 to MPFaster response and higher platelet counts in the IVIg group (*p* = 0.006)\[[@CR159]\]RCT nonblindedIVIg 2 g/kg over 5 days (7 patients), PD 1 mg/kg per day (13 patients) or both IVIg and PD (12 patients)32 acute immune thrombocytopenic purpura adult patientsNo difference in response rates or in requirements for splenectomy or in bleeding\[[@CR160]\]RCT nonblindedIVIg 2 g/kg over 2 days (19 patients) or PD with starting dose of 4 mg/kg per day and then tapering until discontinuation by day 21 (18 patients) or no therapy (16 patients)53 children with acute immune thrombocytopenic purpura and less than 20,000 platelets per microliterBoth IVIg- and PD-treated children reached platelet counts over 50,000 per microliter faster than children not treated (*p* \< 0.001)Median time to reach more than 50,000 platelets per microliter was lower in IVIg group (2 days) than in PD group (4 days), *p* \< 0.001\[[@CR161]\]Partially randomized trial; patient\'s family chose no treatment or treatment (IVIg or CS upon randomization)IVIg 1.6 g/kg over 2 days (12 patients) or MP with starting dose of 30 mg/kg per day for 3 days and then 20 mg/kg per day for 4 days (12 patients) or no therapy (26 patients)50 children with acute immune thrombocytopenic purpura and less than 20,000 platelets per microliterBoth IVIg- and MP-treated children reached platelet counts over 20,000 per microliter and 50,000 per microliter faster than children not treated, *p* \< 0.01Immune thrombocytopenic purpura in HIV\[[@CR162]\]Controlled clinical trialIVIg 2 g/kg of IVIg over 2 days, followed by IVIg 1 g/kg on day 1514 patients with HIV-related thrombocytopenia (median platelet count 17,000/mm^3^)All achieved resolution of their bleeding by day 8, but this was temporary\[[@CR163]\]Controlled clinical trialIVIg 0.04 g/kg per week during 5 weeks13 thrombocytopenic AIDS patientsAll patients responded in the first week but only 4 were responders after 3 monthsChronic immune thrombocytopenic purpura\[[@CR164]\]Prospective noncontrolled trialIVIg 2 g/kg over 2 or 5 days (BT681m, Biotest Pharma GmbH, Dreieich, Germany) in accordance to randomization, followed for 28 days24 chronic immune thrombocytopenic purpura adult patients91.7% of patients underwent a fast raise (in 2--5 days) of platelet count over 50,000 per microliter; at the end of the 28 days of follow-up, half of the patients had still platelet count over 50,000 per microliter\[[@CR165]\]Prospective noncontrolled trialInduction with IVIg 1 or 2 g/kg (Biotransfusion, Roissy, France) over 2 days and 6 more maintenance infusions of IVIg 1 g/kg starting when platelets fell below 50,000 per microliter and then every 2 to 3 weeks unless platelets are over 150,000 per microliter or response is exhausted20 chronic immune thrombocytopenic purpura adult patientsInitial response in all 18 evaluable subjects, 13 complete (\>150,000 per microliter), 5 partial (\>50,000 per microliter); no difference between both induction doses; maintenance: at 90-day failure in 61% (11 of 18), partial response (\>50,000 per microliter in 2 of 18, 11%) and complete response (\>150,000 per microliter in 5 of 18, 28%)Posttransfusional purpura\[[@CR166]\]Case seriesIVIg17 patients with severe thrombocytopenia after blood transfusionIn 16 patients, normal platelet counts were reached within days; 5 patients relapsed and again had a good response to new IVIg administration\[[@CR167]\]Case seriesIVIg 0.4 g/kg per day, for 2--10 days5 patients with severe thrombocytopenia after blood transfusionImmediate raise in platelet count and cessation of bleeding in 4 of 5 patients (80%)\[[@CR168]\]Case seriesIVIg, variable doses ranging from 1 to 2 g/kg per day3 patients with thrombocytopenia after blood transfusionGood response in 2 of 3 patientsHemophagocytic syndrome\[[@CR169]\]Case seriesIVIg6 renal transplant patients with hemophagocytic syndromeGood response in all the cases\[[@CR170]\]Case seriesIVIg7 children with hemophagocytic syndrome treated with IVIg only3 of 7 (43%) survived\[[@CR171]\]Case seriesIVIg 2 g/kg over 2 days in one case, over 5 days in the other2 cases of EBV-associated hemophagocytic syndrome treated with IVIg only2 of 2 (100%) survived\[[@CR172]\]Case seriesIVIg8 children with infection-associated hemophagocytic syndrome treated with IVIg0 of 8 (0%) survived\[[@CR173]\]Case seriesIVIg 1 g/kg per day for 1 or 2 days3 children with infection-associated hemophagocytic syndrome treated with IVIg3 of 3 (100%) survived\[[@CR174]\]Case reportIVIgA healthy patient with CMV-related hemophagocytosisSymptoms and laboratory abnormalities improved dramatically after the onset of the treatmentPOEMS syndrome\[[@CR175]\]Case report2 courses of IVIg 0.4 g/kg per day for 5 days, separated by 3 weeks, adjunctive to radiotherapy49-year-old patient with rapidly progressive polyneuropathy associated with osteosclerotic myelomaAfter 2 courses of IVIg improvement of respiratory and sexual function and gate, disappearance of numbness; doing well after 1 year\[[@CR176]\]Case reportIVIg 0.4 g/kg per day for 4 (case 1) or 5 days (case 2) adjunctive to prednisolone 30--50 mg/dayA 55-year-old man (case 1) and a 43-year-old woman (case 2) with late-stage POEMSNo change in motor and sensory impairment; case 1 continued to deteriorate and died after 6 months due to sepsis and DIC\[[@CR177]\]Case reportIVIg (one course)A patient with POEM and Castleman\'s diseaseNo effectDiffuse B cell posttransplant lymphoproliferative disorder\[[@CR178]\]Case reportIVIg 0.5 g/kg every 15 days for 4 months (case 1) and for 12 and 7 months, respectively (case 2) adjunctive with IFN alpha (2 × 10^6^ IU SC 3 times a week)2 patients with diffuse B cell posttransplant lymphoproliferative disorderComplete disappearance of all lesions after 3 months of the therapy in case 1 and after 7 months in case 2, remission for 47 months and 33 months, respectively*POEMS syndrome* polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes

Acquired hemophilia {#Sec20}
-------------------

### Level of evidence B {#d29e4078}

There is weak evidence that IVIg is useful in the treatment of acquired hemophilia. IVIg may be tried in the case in which CS and cytotoxic agents fail or when facing an emergency situation as an additional therapy IVIg (*strength of recommendation IIa*).

Acquired hypogammaglobulinemia {#Sec21}
------------------------------

### Level of evidence A {#d29e4089}

There is strong evidence that IVIg is of benefit in reducing the number and severity of infections in patients with acquired hypogammaglobulinemia in the context of hematological malignancy (*strength of recommendation I*). While this is true, both cost and the potential of adverse effects, most prominently acute renal failure and thromboembolic phenomena \[[@CR3]--[@CR5]\], prevent a clear-cut recommendation for the use of IVIg in acquired hypogammaglobulinemia. With this in mind, IVIg may be recommended at the replacement dose of 400 mg/kg each 3 to 4 weeks in cases in which severe or recurrent infections have occurred.

Pure red cell aplasia {#Sec22}
---------------------

### Level of evidence C {#d29e4106}

Pure red cell aplasia may be immune-mediated due to a background neoplasia, most frequently hematologic, or due to an immune disease or as an immune response triggered by drugs. It may also occur secondary to parvovirus B19 infection which may also lead to aplastic anemia. Treatment of the causative disease is the most important issue. Weak evidence supports the use of IVIg in pure red cell aplasia. IVIg may however be used in the case in which first-line therapy (i.e., CS and immunosuppressive drugs) fails to achieve a remission (*strength of recommendation IIa*). IVIg is first-line therapy in immunosuppressed hosts in which infection with parvovirus B19 results in pure red cell aplasia.

Acquired von Willebrand syndrome {#Sec23}
--------------------------------

### Level of evidence B and C {#d29e4117}

According to Federici and colleagues \[[@CR6]\], 48% of the cases of acquired von Willebrand syndrome are associated with lymphoproliferative diseases, 15% with myeloproliferative disorders, and 21% with cardiovascular diseases. In another paper, Federici and colleagues \[[@CR7]\] claim that 33% of the reported cases are associated with a monoclonal gammopathy of uncertain significance. Then, the detection and specific treatment of the underlying disease is as important as the immediate therapy of the coagulation disorder. In accordance to the scant existing evidence of IVIg therapy in this disorder, IVIg should be used in cases of standard therapy (desmopressin and factor VIII/von Willebrand factor concentrate) failure and in urgent situations as an addition to such therapy (*strength of recommendation IIb*). IVIg may also be used in the preparation for surgery.

Aplastic anemia {#Sec24}
---------------

### Level of evidence C {#d29e4135}

While idiopathic aplastic anemia can be transient as in the case of parvovirus-B19-induced bone marrow depression, idiopathic aplastic anemia should first be treated with immunosuppressive drugs like CS or cyclosporine or with antithymocyte or antilymphocyte immunoglobulins as well as supportive blood components transfusions. Stem cell transplantation is always the alternative in the case of failure of the aforementioned treatments. Due to the low level of evidence of IVIg for the treatment of idiopathic aplastic anemia, we cannot recommend its liberal use but it may be tried in the case of treatment failure, before stem cell transplantation is performed (*strength of recommendation IIb*).

Autoimmune hemolytic anemia {#Sec25}
---------------------------

### Level of evidence B {#d29e4146}

Immunosuppression with CS and then cytotoxic agents should be used in autoimmune hemolytic anemia before considering IVIg. There is however some evidence that IVIg might be useful and therefore in refractory cases before considering splenectomy it may be worth a try (*strength of recommendation IIb*).

Autoimmune neutropenia {#Sec26}
----------------------

### Level of evidence C {#d29e4157}

Although immune neutropenia may also be an adverse effect resulting from IVIg treatment as have been published elsewhere \[[@CR8]\], IVIg has been used to treat immune neutropenia. The evidence is weak and responses are not as good as those with CS and granulocyte colony-stimulating factor (*strength of recommendation IIb*).

Evans' syndrome {#Sec27}
---------------

### Level of evidence C {#d29e4171}

Evans' syndrome is usually a therapy-resistant condition that has been treated combining CS, IVIg, and immunosuppressive therapy. Although convincing evidence is lacking for the use of IVIg in view of the severity and the refractory nature of several cases of Evans' syndrome, IVIg may be considered among the treatment options generally together with CS with or without immunosuppressive therapy (*strength of recommendation IIb*).

Fetal/neonatal alloimmune thrombocytopenia {#Sec28}
------------------------------------------

### Level of evidence B {#d29e4182}

The only study comparing IVIg against other treatment (CS), although nonrandomized, suggests that IVIg raises the platelet number and prevents intracranial bleeding in a significant percentage of treated patients. The level of evidence is low, but the alternatives for prenatal treatment of fetuses at risk are not better and the risks involved are huge (*strength of recommendation IIb*).

Stem cell/bone marrow transplantation {#Sec29}
-------------------------------------

### Level of evidence A {#d29e4193}

Strong evidence denies any benefit from the use of IVIg around stem cell/bone marrow transplantation, both from the infectious or from the graft-versus-host disease point of views (*strength of recommendation III*).

Hemolytic disease of the newborn {#Sec30}
--------------------------------

### Level of evidence A {#d29e4204}

There is clear evidence for the use of IVIg when facing newborn hemolysis as it reduces the need of plasmapheresis (PP) therapy (*strength of recommendation I*).

Hemolytic transfusion reaction {#Sec31}
------------------------------

### Level of evidence C {#d29e4215}

There is no reliable evidence to recommend the use of IVIg to prevent or to treat hemolytic transfusion reactions (*strength of evidence IIb*).

Hemolytic transfusion reaction in sickle cell disease {#Sec32}
-----------------------------------------------------

### Level of evidence C {#d29e4226}

Apart from two papers reporting two cases and another case, there is no evidence to recommend the use of IVIg either to prevent or to treat hemolytic transfusion reactions in sickle cell patients, specially taking into consideration the additional risk of thrombosis due to a change in the rheologic properties of the blood after IVIg infusion (*strength of recommendation IIb*).

Hemolytic uremic syndrome {#Sec33}
-------------------------

### Level of evidence B {#d29e4237}

There is conflicting evidence that IVIg benefits patients with hemolytic uremic syndrome (*strength of recommendation IIb*).

Thrombotic thrombocytopenic purpura {#Sec34}
-----------------------------------

### Level of evidence B {#d29e4248}

There is no evidence that IVIg benefits patients with thrombotic thrombocytopenic purpura (*strength of recommendation III*).

Heparin-induced thrombocytopenia {#Sec35}
--------------------------------

### Level of evidence C {#d29e4260}

There is low-level evidence that IVIg is useful for this disease. On the other hand, thromboembolic phenomena, which are part of the heparin-induced thrombocytopenia clinical picture, might be enhanced by the rheologic blood changes after IVIg infusion. Therefore, IVIg should not be generally recommended for this disease (*strength of recommendation IIb*).

HIV-associated thrombocytopenia {#Sec36}
-------------------------------

### Level of evidence B {#d29e4271}

Evidence comes only from one crossover randomized placebo-controlled trial which supports the use of IVIg in HIV-associated thrombocytopenia, especially when platelet count is very low or the risk of bleeding is high (*strength of recommendation IIa*).

Acute immune thrombocytopenic purpura {#Sec37}
-------------------------------------

### Level of evidence A {#d29e4282}

Since Imbach's observation \[[@CR1]\], acute ITP has been the prototype of IVIg-responsive immune disease. There is consistent evidence that IVIg is beneficial in children with ITP (*strength of recommendation I*). Notwithstanding this, CS therapy is still the first-line treatment for ITP, and single-dose anti-D immunoglobulin \[[@CR9], [@CR10]\] is a \[[@CR8]\] good alternative for Rh-positive patients. IVIg should be considered when there is bleeding or when the bleeding risk is high or upon failure of other treatments. In adult acute ITP patients, there is no placebo-controlled RCT, but when compared with CS IVIg induces a faster response. Again, CS is the first-line treatment for adults but IVIg may be given in severe or refractory cases. There is weak evidence that IVIg can improve mother and fetal prognosis in pregnancy. IVIg may be used when a fast correction in platelet number is needed.

Immune thrombocytopenic purpura in HIV {#Sec38}
--------------------------------------

### Level of evidence B {#d29e4305}

By the merits of its own research, IVIg may be considered to treat ITP in the context of HIV. Although no hard evidence exists due to the fact that this particular group of patients has not been investigated as well as has non-HIV-related ITP, it will be hard to argue that the recommendation of the latter may not be extended to HIV-related ITP (*strength of recommendation I*).

Chronic immune thrombocytopenic purpura {#Sec39}
---------------------------------------

In chronic ITP, IVIg has so far not demonstrated a plausible benefit. Only prospective noncontrolled trials are available and we found only one evaluating maintenance IVIg for chronic ITP, in which the overwhelming majority of patients had a recrudescence of thrombocytopenia in spite of a good initial response to IVIg (level of evidence and strength of recommendation B-IIb). A small number of patients benefited and therefore IVIg might be tried in drug refractory cases of chronic ITP in which there is a contraindication for splenectomy.

Posttransfusional purpura {#Sec40}
-------------------------

### Level of evidence C {#d29e4321}

Series of patients treated with fast response to IVIg suggest a benefit of IVIg treatment in posttransfusional purpura, although with low-level of evidence. In the context of a patient with severe risk to bleeding or actual bleeding, IVIg can be used if the diagnosis of posttransfusional purpura is made (strength of recommendation IIb).

Hemophagocytic syndrome {#Sec41}
-----------------------

### Level of evidence C {#d29e4329}

Hemophagocytic syndrome is a severe reaction leading to high mortality. Inconsistent and low-level evidence do not warrant a clear-cut recommendation of IVIg for this syndrome. However, due to the lack of effective and standardized treatment in an otherwise highly lethal disease, IVIg may be used along with other therapies like monoclonal antibodies, CS, cytotoxic drugs, and support measures (*strength of recommendation IIb*).

POEMS {#Sec42}
-----

### Level of evidence C {#d29e4340}

There are only anecdotal reports, both showing benefit and lack of benefit. There is no evidence that IVIg has a beneficial effect on polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (*strength of recommendation IIb*).

Diffuse B cell posttransplant lymphoproliferative disorder {#Sec43}
----------------------------------------------------------

### Level of evidence C {#d29e4351}

There is no convincing evidence that IVIg has any beneficial effect in this disease (*strength of recommendation IIb*; Table [4](#Tab4){ref-type="table"}). Table 4The use of intravenous immunoglobulins in infectious diseasesDiseaseRef.Study designIntervention including dose and IVIg preparation usedNumber of patients.Results/responseCytomegalovirus (CMV)\[[@CR179]\]Controlled trialIVIg 0.25 g/kg weekly for 8 weeks, starting on the operative day40 renal transplanted patients with negative serology for CMVEffective prophylaxis, associated with excellent 1-year allograft survivalHuman immunodeficiency virus (HIV) child infection\[[@CR180]\]RCTIVIg 0.4 g/kg or placebo (0.1% albumin) every 28 days372 symptomatic children infected with HIVSignificant reduction in serious infections (*p* = 0.01) and hospitalizations (*p* = 0.03), in the IVIg group only for those entering treatment with CD4+ lymphocyte ≥200; no effect on mortality\[[@CR181]\]Controlled trialIVIg (Gamimune-N, Miles Pharmaceutical Co.), 0.2 g/kg monthly for 1 year135 symptomatic and asymptomatic children with perinatal HIVSignificant reduction in the frequency of bacterial infections in the symptomatic groupHIV-associated thrombocytopenia---see hematology sectionMalaria\[[@CR182]\]RCTAll were treated with IV quinine dihydrochloride; in addition, patients were randomized to receive either IVIg, 0.4 g/kg over 3 h, or placebo31 children with *Plasmodium falciparum* parasitemia and comaOf 16 patients receiving immunoglobulin, 5 (31%) died, and 5 survivors had neurological sequelae; of 15 patients receiving placebo, one (7%) died and 2 had sequelae (trial was stopped)\[[@CR183]\]Controlled trialIVIg was prepared from 180 donors after infection screening; 6 patients were treated with a 0.1-g/kg dose given over 3 days, one with a single 0.02-g/kg dose, and one with a single 0.02-g/kg dose8 Thai patients with *P*. *falciparum* parasitemiaClearance of parasites and symptoms was as fast as or faster than with drugsPostpolio syndrome (PPS)\[[@CR184]\]Multicentered RCT90 g of IVIg during 3 days, repeated after 3 months142 patients: 73 with IVIg and 69 placebosMild improvement in median muscle strength (*p* = 0.03), vitality (*p* = 0.04), no change and quality of life (*p* = 0.3)\[[@CR185]\]RCTPatients were randomized to IVIg, 2 g/kg, or placebo20 patients with PPSNo effect was seen with IVIg treatment on muscle strength and fatigue; however, IVIg patients reported significantly less pain 3 months after treatment\[[@CR186]\]Open clinical trial90 g of IVIg (30 g daily for 3 days)14 patients with PPSSignificant improvement in the quality of life, no change in muscle strength and physical performanceSepsis\[[@CR187]\]Meta analysis of RCT\'s from PubMedDifferent preparations of relatively low doses of IVIg for severe sepsis, mostly surgical patients with gram-negative infections14 RCTs published between 1988 and 2006 were includedSignificant but heterogenic reduction in mortality associated with use of IVIg (*p* \< 0.0005); this result was not confirmed when only high-quality studies were analyzedWest Nile Virus (WNV)\[[@CR188]\]Case report0.4 g/kg IVIg preparation from donors that contained a high titer of anti-WNV antibodies (1:1,600)42-year-old male lung-transplant recipient with severe WNV encephalitisComplete disappearance of signs and symptoms within 48 h\[[@CR189]\]Case reportIVIg 0.4 g/kg for 5 days (Omr-IgG-am, Omrix Biopharmaceutical Ltd., Tel Hashomer, Israel)70-year-old with chronic lymphatic leukemia and coma due to WNVLevel of consciousness returned to normal over 5 daysProphylaxis for infections (in intensive care units (ICU))\[[@CR190]\]RCTPatients received standard IVIg, 0.4 g/kg, hyperimmune globulin (HG), 0.4 g/kg, or placebo, weekly, for a maximum of 4 doses329 postsurgical patients admitted to the surgical ICUSignificantly lower infections and hospital days in the IVIg group vs. placebo or HG (*p* = 0.003); no lesser mortality/shock\[[@CR191]\]RCTPatients received IVIg (36 g) versus 0.03% albumin150 trauma patients in ICU ventilated for \>24 hDecreased overall incidence of infection (*p* = 0.02) and antibiotic need in IVIg group\[[@CR192]\]RCTTen patients received IVIg and ten albumin20 patients with extensive thermal injuryNo statistically significant difference was found between mortality rates of the groups\[[@CR193]\]RCT18 received IVIg, 0.4 g/kg, and 14 placebo within 48 h of admission33 children (mean age, 6.67 years) with severe head injuriesNo effect on the incidence of secondary infections\[[@CR194]\]RCTWithin 12 h of ICU admission, 1 g/kg of IVIg or human albumin divided over 4 days39 trauma patients in an ICUNo difference in overall infection rates, but fewer pneumonias (*p* = 0.003) and non-catheter-related infections (*p* = 0.04); no difference in ICU length of stay or antibiotic use\[[@CR195]\]RCTPatients were randomly assigned to either 20 g IVIg or saline40 postoperative open-heart surgery patients with cutaneous anergy preoperativelyInfection incidence 5% in IVIg versus 43% placebo (*p* = 0.007)Prophylaxis for infections (in immune-compromised patients)\[[@CR142]\]RCT82 received IVIg weekly, 0.5 g/kg, from the initiation of cytotoxic therapy to the resolution of neutropenia and 88 were untreated controls170 neutropenic patients undergoing BMT or severe myelosuppressive therapyThe use of IVIg did not prevent infection; fewer deaths occurred among controls due to a higher incidence of fatal hepatic veno-occlusive disease in patients receiving IVIg\[[@CR196]\]RCTMonthly IVIg 0.4 g/kg or placebo for 1 year82 patients with stable multiple myelomaLess infection sepsis in the IVIg group (*p* = 0.002)Necrotizing fasciitis (NF)\[[@CR197]\]Controlled trial16 were treated with ≥1 mg/kg of IVIg; all were treated with antibiotics and debridement20 patients with NFNo difference in case fatality\[[@CR198]\]Controlled trialPatients were treated with effective antimicrobials, high-dose IVIg; surgery was either not performed or only limited exploration was carried out7 patients with severe NFAll patients survived\[[@CR199]\]Controlled trialPatients that had hypotension and multiorgan failure were treated with a single dose of IVIg 50 g in addition to antibiotics11 patients with toxic shock syndrome with or without NFTen patients were fully recovered\[[@CR200]\]Case reportPatient declined on antibiotic therapy and was treated with IVIg, 0.4 g/kg (Omr-IgG-am 5% IV, Omrix, Israel)A renal transplant lupus patient with NFA marked improvement in patient\'s condition on the next dayRecurrent otitis media (OM)\[[@CR201]\]RCTIVIg or placebo22 otitis-prone children, 1--4 years oldNo significant difference in the frequency of OM attacks or other respiratory tract IVIg group\[[@CR202]\]Controlled trialIVIg9 children with recurrent sinopulmonary infections which failed to improve after antibiotic TxSignificant decrease in the episodes of sinusitis and OMVaricella (transmission prevention)\[[@CR203]\]Controlled trialIVIg prophylaxis (single-dose 0.5 g/kg) administered soon after birth or postnatal contact, either alone or with IV acyclovir24 newborns whose mother had a varicella rash within 14 days before and after deliveryTreatment with IVIg + acyclovir effectively prevented perinatal varicella\[[@CR204]\]Controlled trialIVIg 0.04 to 0.045 g/kg per day for 5 to 9 days was given soon after birth, along with acyclovir5 infants whose mothers had varicellaSome had a mild--moderate transient rash but none had constitutional symptomsVaricella (pulmonary disease)\[[@CR205]\]Case reportIVIg and IV acyclovir2 cases of varicella infection complicated by severe pulmonary involvement previously healthy adultsGradual clinical improvement after administration\[[@CR206]\]Case reportIVIg, 2.5 g every 12 h, with IV acyclovir and ABxA healthy adult with severe respiratory failure due to varicella pneumoniaGradual clinical improvement after administration\[[@CR207]\]Case reportIVIg and IV acyclovir32-year-old patient with varicella and ARDSQuick improvement\[[@CR208]\]Case reportPatient was mechanically ventilated and treated with IVIg and acyclovir26-year-old with ARDS secondary to varicella pneumoniaQuick improvementVaricella (complicated with ITP)\[[@CR209]\]Case reportIVIgITP in a 3-year-old girl with an active varicella infectionDrastically improved bleeding and active varicella infection\[[@CR210]\]Case reportIVIg, 0.4 g/kg per day for 3 days, and acyclovir40-year-old with bleeding due to varicella-related ITPThe platelet counts increased to 254,000 per microliter over the next 5 days, and the skin rashes associated with varicella subsided within a week

Cytomegalovirus {#Sec44}
---------------

### Level of evidence B {#d29e5121}

IVIg is not used for the treatment of CMV infection but may be helpful in treatment of hemophagocytic syndrome related to CMV and other viruses (see hematology section); there is some evidence for its effectiveness in preventing seroconversion in transplant patients who are immunosuppressed (*strength of recommendation I*).

Human immunodeficiency virus {#Sec45}
----------------------------

### Level of evidence B {#d29e5132}

IVIg can reduce infections in children with perinatal HIV but has not been proven to reduce mortality (*strength of recommendation IIa*).

Malaria {#Sec46}
-------

### Level of evidence B {#d29e5144}

No evidence for the effectiveness of IVIg in the treatment in malaria exists (*strength recommendation III*).

Postpolio syndrome {#Sec47}
------------------

### Level of evidence A {#d29e5155}

Postpolio syndrome (PPS) typically affects survivors of poliovirus infection, 15--20 years after the original infection, with fatigue, muscular weakness, and pain. There are two RCTs demonstrating some inconsistent evidence for the effectiveness of IVIg treatment on quality of life, pain, and muscle strength in patients with PPS (*strength of recommendation IIa*).

Sepsis {#Sec48}
------

### Level of evidence A {#d29e5166}

Sepsis is a life-threatening condition, resulting mainly from the patient's immune response to a severe infection. Significant but heterogenic reduction in mortality with IVIg treatment in septic patients was demonstrated in a meta-analysis of 14 RCTs. These results were not confirmed when only high-quality studies were analyzed (*strength of recommendation IIa*).

West Nile {#Sec49}
---------

### Level of evidence C {#d29e5177}

Infection with West Nile virus can cause fatal encephalitis in immunosuppressed and elderly patients, in which case effective treatment is lacking. The effectiveness of IVIg in these situations is supported by a few case reports and may be considered (*strength of recommendation IIa*).

Infection prophylaxis---in intensive care units {#Sec50}
-----------------------------------------------

### Level of evidence A {#d29e5188}

Treatment with IVIg has not proven to reduce infectious-related mortality in postsurgical patients, but there is inconsistent evidence that IVIg reduces ICU-related infections and hospital stay in these patients (*strength of recommendation IIa*).

Infection prophylaxis---in immune-compromised patients {#Sec51}
------------------------------------------------------

### Level of evidence A {#d29e5199}

There is conflicting evidence regarding the usefulness of IVIg treatment for these patients. It should be taken into consideration that patients treated with IVIg after bone marrow transplantation (BMT) may have a higher incidence of fatal hepatic veno-occlusive disease (*strength of recommendation IIa*).

Necrotizing fasciitis {#Sec52}
---------------------

### Level of evidence B {#d29e5210}

Necrotizing fasciitis is caused by deep-skin infection with bacteria, mainly group A streptococcus. The mainstay of nuclear factor treatment is prompt surgical exploration and antibiotic therapy. IVIg might have additional benefit to antibiotic therapy for treatment of patients who refuse surgery or are not surgical candidates. (*strength of recommendation IIa*).

Recurrent otitis media {#Sec53}
----------------------

### Level of evidence B {#d29e5221}

There is weak evidence that IVIg is useful in the treatment of recurrent otitis media (*strength of recommendation IIb*).

Varicella {#Sec54}
---------

### Level of evidence B {#d29e5232}

Some evidence that IVIg is effective in preventing perinatal transmission of varicella. IVIg may also be used for treatment adults with severe respiratory failure due to varicella pneumonia (*level of recommendation IIa*; Table [5](#Tab5){ref-type="table"}). Table 5The use of intravenous immunoglobulins in gyneco-obstetric diseasesDiseaseRef.Study designIntervention including dose and IVIg preparation usedNumber of patientsResults/responsePerinatal hemochromatosis\[[@CR211]\]Case--control study; previous patients\' pregnancies used as their own controlsIVIg 1 g/kg weekly since week 1815 patients (16 pregnancies) with previous pregnancies resulting in perinatal hemochromatosisGood outcome (survived with or without medical therapy) in 15 gestations treated with IVIg; in historical controls of the same mothers, 2 pregnancies had good outcome and 13 had poor outcome (fetal or neonatal death, or liver failure necessitating liver transplantation), *p* = 0.0009Recurrent pregnancy loss excluding antiphospholipid syndrome\[[@CR212]\]Meta-analysisIVIg442 women with recurrent spontaneous miscarriages (at least 3) from eight RCTs; secondary recurrent miscarriages are defined as those in women that had at least a previous successful birthNo significant difference (*p* = 0.21) between women with primary recurrent miscarriages treated with IVIg or without; however, there was a significant improvement of live births when IVIg was given to women with secondary recurrent miscarriages (*p* = 0.03)\[[@CR213]\]Meta-analysisIVIg versus placebo or no treatment303 women with idiopathic recurrent abortions from 8 RCTsNo benefit of IVIg on recurrent pregnancy loss\[[@CR214]\]Meta-analysisIVIg246 women with recurrent spontaneous miscarriages (at least 2) from 5 RCTs; secondary recurrent miscarriages are defined as those in women that had at least a previous successful birthNo significant difference between women with primary recurrent miscarriages treated with IVIg or without; not enough patients to conclude something about women with secondary recurrent miscarriages but there was a trend towards improvement\[[@CR215]\]RCT29 women received IVIg, 29 placebos; IVIg was administered from weeks 5--10 weekly at 0.8 g/kg every week, from weeks 10--20 at 0.8 g/kg every 2 weeks and from weeks 20--26 at 1 g/kg every 2 weeks; no IVIg as given after week 2658 women with recurrent spontaneous miscarriages (at least 4); secondary recurrent miscarriages are defined as those in women who had at least a previous pregnancy that progressed to week 26 or moreNo benefit in primary recurrent miscarriages but a trend towards improvement among women with secondary recurrent miscarriages\[[@CR216]\]Meta-analysisIVIg in 125 patients, 115 received placebo240 women with recurrent spontaneous miscarriagesNo benefit of IVIg\[[@CR216]\]RCTIVIg (Gammonativ) 20 g every 3 weeks, 5 courses after confirmation of pregnancy41 women with recurrent spontaneous miscarriagesNo benefit of IVIg neither for women with primary or secondary recurrent miscarriage\[[@CR217]\]RCT22 patients received IVIg (Sclavo) 50 g over 2 days upon confirmation of pregnancy (weeks 5--7) and again 25 g 3 weeks later46 women with recurrent spontaneous miscarriagesNo benefit of IVIg\[[@CR218]\]RCT47 patients received IVIg 0.5 g/kg every month starting up to 4 months before pregnancy and until weeks 28--32 of pregnancy; 48 patients received placebo95 women with recurrent spontaneous miscarriages (2 or more)More live births in women receiving placebo (*p* = 0.04)\[[@CR219]\]RCTIVIg (Nordimmun, Novo-Nordisk, Gentofte, Denmark) 25--40 g per dose according to patient weight every 2 weeks until week 34 of pregnancy or placebo34 women with secondary recurrent spontaneous abortion (subsequent to a birth or including at least one second trimester miscarriage)More live births but not statistically significant in the IVIg group (52.9% against 29.4%)\[[@CR220]\]RCTIVIg initial dose 30 g, then 20 g every 3 weeks until week 25 (Verum, Immuno GmbH, Heidelberg, Germany) or placebo64 women with primary recurrent spontaneous abortionNo benefit of IVIgRecurrent pregnancy loss in antiphospholipid syndrome\[[@CR221]\]Meta-analysisIVIg given in addition to heparin and aspirin58 women with recurrent miscarriages due to antiphospholipid syndrome in 2 RCTsIncreased risk of pregnancy loss or premature birth in the group receiving IVIg\[[@CR222]\]Randomized trial21 women received IVIg (IgVENA N; Sclavo, Siena, Italy) at the dose of 0.8 g/kg over 2 consecutive days as initial dose followed by 0.4 g/kg each month up to week 31; 19 women received aspirin 75 mg/day up to week 34 + heparin 5,700 IU/day up to week 3740 women with at least 3 abortions due to antiphospholipid syndrome were treated since conception with IVIg or heparin + aspirinMore live births (84% against 57%, not significant difference) in the aspirin + heparin group (*p* = 0.06)\[[@CR223]\]RCTIVIg 2 g/kg (Gamimune-N, Bayer Corporation, West Haven, CT, USA) over 2 days every 4 weeks through 36 weeks' gestation16 pregnant women (no more than 12 weeks\' gestation) with recurrent miscarriages due to antiphospholipid syndrome received low-dose aspirin and heparin and received random IVIg or placeboNo benefit of IVIg\[[@CR224]\]Prospective two-center trial study29 were treated with PD and LDA; 53 received IVIg 0.5 g/kg (Alphaglobin, Grifols International, Pisa, Italy) for 2 consecutive days, once a month from the 5th to the 32nd week of pregnancy82 pregnant women with a history of recurrent fetal loss and APSLive-birth rates were equivalent between groups (78% vs 76%), mean birth weight was higher in the IVIg group gestational hypertension and diabetes were found significantly more often in the PD group (14% vs 5%), respectively (*p* \< 0.05)\[[@CR225]\]Case seriesPatients were treated with heparin (15), LDA (18), and CS (6); additionally, they received IVIg 0.4 g/kg for 5 days monthly from the first or early second trimester19 pregnancies of 15 women with APS and recurrent fetal lossThe live-birth rate was 84%; compared to approximately 70% described in literature without IVIg\[[@CR226]\]Controlled trialIn phase III, they received heparin + LDA with or without IVIg121 women with APS, who failed to achieve live births after 2 IVF attempts with heparin + LDAThe birth rate was 41% when IVIg was added and anti-PS or anti-PE involving IgG or IgM isotypes were present, as compared with 17% when H + A alone was administered; the IVF outcome did not improve when IVIg was administered in association with any other single APS antibodies\[[@CR227]\]Controlled trialIVIg 0.3 g/kg every 3 weeks until the 16th to 17th week of pregnancy38 women after 3 or more consecutive first trimester spontaneous abortions and APSPregnancy proceeded beyond the first trimester in 34 of the patients (89.4%), and 31 patients (81.4%) gave birth to healthy infants at 37 to 42 weeks\' gestation\[[@CR228]\]Case controlIVIg 0.5 g/kg for 2 days from the fifth week of pregnancy and repeated every 4 weeks until the 33rd week of gestation14 women with a history of recurrent spontaneous abortion and APLANo significant biometrical differences between the groups were seen; no fetal or neonatal growth retardation was seenData were compared to 70 matched uneventful pregnanciesPremature rupture of membranes\[[@CR229]\]RCTIVIg (Pentaglobin, Biotest, Frankfurt/Main, Germany) 20 g, 24--48 h after premature rupture of membranes; thereafter, 10 g was administered in weekly intervals18 women with premature rupture of membranesInfants in treated group showed less laboratory and clinical signs compatible with prenatally acquired infection (*p* \< 0.002); less chorioamnionitis in treatment group (*p* \< 0.036)Failure of *in vitro* fertilization\[[@CR230]\]Meta-analysisIVF along with or without IVIgWomen with IVF failureImprovement in live-birth rate (*p* = 0.012)\[[@CR231]\]RCTIVIg (Gamimune 5%, Bayer Canada Inc., Etobicoke, Canada) 0.5 g/kg or placebo (saline), first infusion on the day of embryo transfer or during preceding 72 h, second infusion 4 weeks later upon evidence of embryonic heart activity51 women after IVF failureNo significant improvement in implantation, pregnancy, or live birth rate

Perinatal hemochromatosis {#Sec55}
-------------------------

### Level of evidence B {#d29e5753}

Although the best level of evidence is not strong, the improvement shown for treated pregnancies is beyond the natural possibility of a subsequent spared pregnancy which has been estimated to be approximately 40% ( Gissen 2004 \#110). In view of this data and the difficulty for large RCTs, IVIg may be considered to prevent recurrent perinatal hemochromatosis (*strength of recommendation IIa*).

Recurrent pregnancy loss excluding antiphospholipid syndrome {#Sec56}
------------------------------------------------------------

### Level of evidence A {#d29e5766}

There is evidence that IVIg improves the outcome of pregnancy in secondary recurrent miscarriage (in women that had a previous pregnancy that reached at least the second trimester (*strength of recommendation IIb*)). This has so far not been shown for primary recurrent miscarriage (*strength of recommendation III*).

Recurrent pregnancy loss due to antiphospholipid syndrome {#Sec57}
---------------------------------------------------------

### Level of evidence A {#d29e5781}

The evidence is against the use of IVIg in pregnancy of women affected by antiphospholipid syndrome (*strength of recommendation III*).

Prevention of infection after premature rupture of membranes {#Sec58}
------------------------------------------------------------

### Level of evidence B {#d29e5792}

Evidence from a small RCT indicates that IVIg may reduce the rate of fetal infection after premature rupture of membranes (*strength of recommendation IIa*).

Failure of in vitro fertilization {#Sec59}
---------------------------------

### Level of evidence A {#d29e5803}

The evidence is scarce but the only meta-analysis based on data from three RCTs found a benefit in the number of live births in women treated with IVIg. After in vitro fertilization (IVF) failure, IVIg along with IVF techniques may be weighted (*strength of recommendation IIb*; Table [6](#Tab6){ref-type="table"}). Table 6The use of intravenous immunoglobulins in cardiac diseaseDiseaseRef.Study designIntervention including dose and IVIg preparation usedNumber of patientsResults/responseCongestive heart failure (CHF)\[[@CR13]\]RCTOctagam (Octapharma) 0.4 g/kg per day for 5 days followed by monthly dose of 0.4 mg/kg for 5 months, compared with placebo40 patients with symptomatic CHF (NYHA II/III) and ejection fraction (EF) \<40% due to idiopathic dilated cardiomyopathy (42.5%) or secondary to ischemic heart disease; 20 patients (9 idiopathic DCM, 11 coronary artery disease) received IVIg; 20 patients received placeboIVIg induced significant increase of EF by means of 5 EF units, regardless of the cause of CHF, compared to no significant change of EF in the placebo group; improved quality of life in 73% compared to 40% in placebo group; *p* value \< 0.05Dilated cardiomyopathy (DCM)\[[@CR12]\]RCTGamimune N, 10% (Bayer Corporation), 1 g/kg IV each day on 2 consecutive days, compared to placebo62 patients with new-onset DCM and EF ≤40% (with symptoms for less than 6 months); both idiopathic DCM and myocarditis patients were included; 33 patients received IVIg, and 29 patients were treated with placeboMean EF improved from 0.25 ± 0.08 to 0.41 ± 0.17 following 6 months for all patients; there was no significant difference in EF improvement between IVIg and placebo groupPeripartum cardiomyopathy (PPCM)\[[@CR232]\]Retrospective study, case series2 g/kg of IVIg given as 1 g/kg q.d. on 2 consecutive days along with conventional therapy, compared to conventional therapy alone17 patients with PPCM; 6 received IVIg; all with NYHA class II--IV and EF \< 40%, within 6 months from deliveryIn the control group, 1 patient died (9.09%), and others had a mean improvement of EF by 13 ± 13 EF units, compared to 26 ± 8 EF units in the IVIg group; *p* value 0.042Myocarditis\[[@CR233]\]Case seriesTotal dose of 1 to 2 g/kg IVIg over 48 h (Venilon, Venoglobulin-IH, and Polyglobin-N preparations were used); all patients received conventional therapy9 patients: 6 patients with acute myocarditis, 3 patients with acute dilated cardiomyopathy; NYHA III and IVMean EF improved significantly, from 19.0 ± 7.5% to 35.4 ± 9.1% following IVIg treatment; *P* value \< 0.01\[[@CR234]\]Prospective nonrandomized trialIVIg (Immuno AG, Vienna), total dose of 2 g/kg over a maximum of 24 h; some of the IVIg groups were treated with an additional dose of 1 g/kg a week later, compared with conventional therapy46 patients with acute onset disease and severely depressed EF; 21 patients received IVIg; a control group of 25 patients was collected from retrospective filesThere was no significant change of survival in the IVIg group compared to control; IVIg group had a higher fractional shortening than control during 3- to 6-month follow-up period; the control group failed to normalize EF; *p* value 0.033Chronic idiopathic pericarditis (CIP)\[[@CR20]\]Case seriesFive monthly cycles of 0.4 g/kg per day for 5 consecutive days, followed by administration every 2 months4 patients with CIPRemarkable response in 3 patients, and a long-standing remission with no need for further steroid treatment; 1 patient with partial responsePericardial diseases\[[@CR18]\]Case reportTotal dose of 2 g/kg of IVIg, and 100 mg/kg per day of acetylsalicylic acid for 14 days1 patient with Kawasaki disease, left anterior descending artery aneurysm and septated pericardial effusion2 weeks following treatment initiation, there was disappearance of the pericardial effusion and no change of the coronary aneurysm\[[@CR16]\]Case reportIVIg treatment starting at the 16th day following initial presentation, total of 2 g/kg, and 30 mg/kg per day of MP for 5 days1 patient with Kawasaki disease, complicated by cardiac tamponadeFailure of treatment and need for salvage pericardiocentesis\[[@CR19]\]Case seriesLow-dose IVIg therapy---approximately 0.5 g/kg every 5 ± 2 weeks for 6 ± 6 courses62 lupus patients, of which several developed pericardial disease60% of affected patients had resolution of pericardial involvementKawasaki disease (KD)\[[@CR235]\]Meta-analysisLow (≤80 mg/kg) and high doses (\>80 mg/kg) of aspirin and low (≤1 g/kg) to high doses (\>1 g/kg) of IVIg over 3--5 daysReview of all published papers from 1967 to 1993; 30--60 days of follow-upThe rates of coronary aneurysms were significantly reduced due to IVIg therapy compared to aspirin alone; high-dose IVIg had lower aneurysm rates compared with low-dose therapy; higher aspirin dose did not alter outcome; *p* value \< 0.0001\[[@CR236]\]Meta-analysis of RCTPatients received: (1) various doses of IVIg, plus aspirin, versus placebo; (2) different doses of IVIg (0.1, 0.2, 0.4 g/kg for 5 days); (3) IVIg 0.4 g/kg for 5 days Vs 2 g/kg once; (4) comparison between 4 types of preparations16 RCTs of patients with KD(1) Significant decrease in new CAAs, fever, and hospitalization at 30 days with IVIg RR (95% CI) = 0.74 (0.61 to 0.90) but only trend at 60 days (*p* = 0.06); (2) dose comparisons showed a decrease in the number of new CAAs with increased dose; (3) less CAA for 2 g/kg once RR (95%) = 4.47 (1.55 to 12.86); (4) no difference\[[@CR237]\]Multicenter RCTIVIg 0.4 g/kg for 4 days, with or without aspirin153 patients (78 with KD, 75 controls)Reduction of echocardiogram-proven CAA from 23% to 8% at 2 weeks (*p* = 0.01) and from 18% to 4% at 7 weeks (*p* = 0.005)\[[@CR238]\]Case control studyIVIg 2 g/kg per day at 1--5 or 5+ days from fever onset178 patients with KD (89 in each group)Patients treated within 5 days had shorter fever duration (*p* \< 0.001) and less CAA at 1 year (*p* = 0.02)\[[@CR239]\]RCTIVIg 2 g/kg per dose and aspirin; four different brands were used in four groups: Venoglobulin-S (brand A; Alpha Therapeutics, Los Angeles, CA, USA), Gamimune\_ N (brand B; Bayer Therapeutics, Elkhart, IN, USA), Intraglobin F (brand C; Biotest Pharma, Dreieich, Germany), "CBSF" human immunoglobulin (brand D; Scottish National Blood Transfusion Service Protein Fractionation Center, Edinburgh, Scotland, UK)435 patients with KDPatients receiving brand C had higher rates of CAAs (*p* = 0.01), nonresponsiveness (*p* = 0.001) and giant aneurysm (*p* = 0.008)\[[@CR240]\]RCTPatients were divided to 2 groups receiving IVIg 1 or 2 g/kg, plus aspirin242 children with KDThere was no significant difference in the incidence of CAL (*p* \> 0.05)\[[@CR241]\]Multicenter prospective RCTGroup A: Tx with IVIg 2 g/kg and additional 2 g/kg for nonresponders; group B: IVIg 1 g/kg, and additional dose first 1 g/kg then 2 g/kg for nonresponders; IVIg used: Venilon (Teijin Pharma, Japan), Venoglobulin-IH (Venesis, Japan) or Polyglobin-N (Bayer Yakuhin, Japan)109 patients with KD divided to 2 groupsNo significant difference in CAA between the patients; discriminate analysis suggested that 52.4% of the patients in group A could be treated with 1 g/kg IVIg only\[[@CR242]\]Multicenter RCTSingle infusion of 2 or 0.4 g/kg for 4 days; both received aspirin (100 mg/kg per day through the 14th day of illness, then 3 to 5 mg/kg per day)549 children with KDSingle-dose patients had less fever (*p* = 0.001), inflammatory markers, and CAA (*p* = 0.004)Rheumatic fever (RF)\[[@CR243]\]RCTIVIg (Intragam, from Common wealth Serum Laboratories) 1 g/kg on days 1 and 2 and 0.4 g/kg on days 14 and 2859 patients with RF, diagnosed according to Jones criteria; 27 patients received IVIg and 32 patients received placeboIVIg did not affect the natural history of RF during 52 weeks of follow-upCongenital heart block\[[@CR26]\]Case series1 gm/kg IVIg (Sandoglobulin; Novartis, Bern, Switzerland), at 14th and 18th weeks of gestation; PD (40 mg/day) from the 14th week, which was tapered down to 10 mg/day8 pregnant women with past history of an affected child with neonatal lupus1 child was born with erythematosus skin rash, and 1 child had congenital heart block---interestingly, his mother was the only patient that refused PD intakeAwaiting for cardiac transplantation\[[@CR244]\]Controlled trial1 to 3 monthly courses of IVIg 2 g/kg administered in 4 divided daily doses or high-dose IVIg therapy (3 g/kg) in poorly responsive patients; all patients received monthly 0.5--1.0 g/m^2^ cyclosporine16 sensitized patients with left ventricular assist device (LVAD) awaiting cardiac transplantation; results were compared to plasmapheresis (*n* = 4) and to cyclosporine alone (*n* = 28)Within 1 week of infusion of IVIg, the reactivity of IgG antibodies for allogeneic HLA class I molecules was reduced by a mean of 33%; high-dose IVIg for unresponsive patients resulted in a mean reduction of 20%; IVIg has earlier onset of action and greater efficacy than plasmapheresis; waiting time for donation was significantly reduced from 7.1 to 3.3 months; *p* value \< 0.05\[[@CR245]\]Retrospective, nonrandomized, controlled trialIVIg, 10 g daily for 3 days or conventional therapy following LVAD transplantation51 nonsensitized patients with CHF, who received left ventricular assist device transplantation received either IVIg (*n* = 26) or conventional therapy (*n* = 25)Low-dose IVIg therapy failed to reduce sensitization rate in nonsensitized LVAD patients who received blood transfusion during bridge time to cardiac transplantation\[[@CR246]\]Case seriesIVIg 2 g/kg given 1 day before the Norwood procedure, repeated 3 weeks and 4 months later7 infants with hypoplastic left heart syndrome who underwent Norwood procedure with cryopreserved allograft pulmonary artery patchIVIg did not prevent sensitization of the previously unsensitized patients

Congestive heart failure {#Sec60}
------------------------

### Level of evidence B {#d29e6370}

A randomized double-blind study has demonstrated significant increase of ejection fraction (EF) and improved quality of life following IVIg administration, regardless of the congestive heart failure (CHF) cause. CHF is a proinflammatory state due to an increase of cytokines such as TNF-α and interleukin (IL)-1. Some of the cytokines have been shown to induce myocardial dysfunction due to negative inotropic effect \[[@CR11]\]. Another possible mechanism in CHF pathogenesis is mediated by anti-β1 adrenergic receptor (*strength of recommendation IIa*).

Dilated cardiomyopathy {#Sec61}
----------------------

### Level of evidence B {#d29e6384}

Dilated cardiomyopathy (DCM) is caused by various triggers or may be idiopathic. Immune abnormalities and autoantibodies may play a role in the pathogenesis. Nevertheless, no significant effect was noted following IVIg administration in recent-onset DCM compared to placebo \[[@CR12]\]. A trial on 17 patients with idiopathic DCM showed significant improvement of EF and quality of life compared with placebo \[[@CR13]\]. Therefore, IVIg treatment in DCM remains controversial, and it is possible that IVIg treatment is beneficial in specific subpopulation and when treatment is initiated at a certain time window (*strength of recommendation IIb*).

Peripartum cardiomyopathy {#Sec62}
-------------------------

### Level of evidence C {#d29e6401}

Peripartum cardiomyopathy (PPCM) is a rare disorder. It is believed that autoimmune mechanisms play a role in the pathogenesis. In a small nonrandomized retrospective trial, there was a significant improvement of EF following IVIg administration compared with conventional treatment. Although there is partial evidence of IVIg effectiveness in PPCM, its use should be considered due to the generally poor prognosis of PPCM patients who show no clinical improvement (*strength of recommendation IIa*).

Myocarditis {#Sec63}
-----------

### Level of evidence B {#d29e6412}

Treatment with CS or cytotoxic agents was found ineffective \[[@CR14], [@CR15]\]. In an RCT trial of 62 patients with new-onset DCM of which some had myocarditis \[[@CR12]\], there was no significant difference in EF improvement between IVIg and placebo group. Nevertheless, in a prospective nonrandomized trial, there was a significant improvement of fractional shortening compared to control. We conclude that further research is warranted regarding IVIg use in myocarditis due to inconclusive results (*strength of recommendation IIb*).

Pericardial diseases {#Sec64}
--------------------

### Level of evidence C {#d29e6432}

Pericardial involvement in Kawasaki disease may be seen in 6.3% to 24.5% of patients and may be complicated by cardiac tamponade despite IVIg therapy \[[@CR16], [@CR17]\], occasionally due to rupture of coronary aneurysms. There is a consensus that IVIg significantly decreases coronary aneurysms, but little is known regarding direct effect on the pericardium in the setting of mucocutaneous lymph node disease. It seems that septated pericarditis in Kawasaki disease response dramatically to IVIg but further research is warranted \[[@CR18]\] (*strength of recommendation IIb*).

Low-dose IVIg therapy was found to be beneficial in 60% of lupus patients with pericarditis in a case series \[[@CR19]\] (*strength of recommendation IIa*).

Chronic idiopathic pericarditis (CIP) appears in up to 25% of acute pericarditis cases. It may be associated with viral infections and autoantibodies \[[@CR20]\]. There is limited evidence on the role of IVIg as an alternative therapy for prolonged steroid or colchicine treatment in CIP (*strength of recommendation IIa*).

Atherosclerosis {#Sec65}
---------------

Atherosclerosis is believed to be mediated also by humeral and cellular immune mechanisms. There are accumulating data that support a role of IVIg in prevention of atherosclerosis. Possible mechanisms include decrease of matrix metalloproteinase 9 secretion from mononuclear cells \[[@CR21]\], increase of IL-10 \[[@CR11]\], and decrease of oxidized low-density lipoprotein uptake by macrophages \[[@CR22]\]. Nevertheless, clinical trials are required in order to establish the relationship between IVIg use and atherosclerosis therapy.

Kawasaki disease {#Sec66}
----------------

### Level of evidence A {#d29e6482}

It is the leading cause of acquired heart disease in the USA. Kawasaki disease is an FDA-approved absolute indication for IVIg therapy. The frequency of CA aneurysm development and associated morbidity and mortality have been dramatically decreased as a result of IVIg therapy when given within 10 days following the onset of fever. A single dose of 2 g/kg of IVIg over 10 H is usually recommended along with a high dosage of aspirin \[[@CR23]\]. Failure of IVIg treatment in Kawasaki disease and the need for several consecutive IVIg doses is usually caused by delayed initiation of treatment \[[@CR16]\]. Detailed treatment algorithms may be found elsewhere \[[@CR24]\] (*strength of recommendation I*).

Rheumatic fever {#Sec67}
---------------

### Level of evidence B {#d29e6502}

Because there is no efficient treatment for established rheumatic carditis, several agents has been proposed in an attempt to change the natural history. IVIg has failed to change clinical outcome and disease progression and therefore is not recommended for treatment of acute rheumatic fever (*strength of recommendation III*).

Congenital heart block in neonatal lupus erythematosus {#Sec68}
------------------------------------------------------

### Level of evidence C {#d29e6514}

NLE is a rare disease that is associated with anti-Ro and anti-La autoantibodies \[[@CR25]\]. A single case series of eight subjects had nonconclusive results regarding the effect of IVIg and PD in prevention of congenital heart block \[[@CR26]\] (*strength of recommendation IIb*).

Cardiac transplantation {#Sec69}
-----------------------

### Level of evidence C {#d29e6531}

IVIg has anti-idiotypic properties, as well as human leukocyte antigen molecules that may neutralize high panel reactive antibodies in sensitized patients awaiting cardiac transplantation. There is some evidence for IVIg benefit in patients with left ventricular assist device who are awaiting cardiac transplantation (strength of recommendation IIa). Nevertheless, IVIg did not reduce sensitization in previously unsensitized patients who underwent Norwood procedure (*strength of recommendation III*; Table [7](#Tab7){ref-type="table"}). Table 7The use of intravenous immunoglobulins in ophthalmic diseaseDiseaseRef.Study designIntervention including dose and IVIg preparation usedNumber of patientsResults/responseOphthalmic IgA bullous disease\[[@CR247]\]Case reportMonthly IVIg treatment, 4 g/kg per month, with graduate discontinuation following clinical improvement1 patient with chronic cicatrizing conjunctivitis due to linear IgA bullous disease with poor response to topical or systemic CSImprovement of clinical symptoms with maximal effect 10--12 days following infusion; decrease of circulating IgA anti-97-kDa epidermal proteinMucous membrane pemphigoid (MMP)\[[@CR27]\]Nonrandomized controlled trialIVIg, 2 g/kg per cycle, cycles were repeated every 2--4 weeks, compared to conventional immunosuppressive therapy16 patients that were equally divided to control and IVIg groupRemission was achieved after 4 months in IVIg group vs 8.5 months in control group; IVIg had less recurrence and decreased progression; *p* value \< 0.05Ocular Behcet\'s disease\[[@CR90]\]Case seriesIVIg 0.4 g/kg per day: 5 times in first week, 3 more in the next months and once every 20 days for total of 3 months4 patients refractory to CS and cyclosporine AControl of acute inflammation and preservation of remission for 1 year; marked improvement of visual acuityOptic neuritis\[[@CR248]\]RCT27 patients were treated with IVIg (Gamimune N; Bayer Pharmaceutical Division, West Haven, CT, USA) 0.4 g/kg per day for 5 days followed by 3 monthly single cycles vs placebo (*n* = 28)55 patients with multiple sclerosis and visual loss due to optic neuritisNo difference between treatment groups was observed; there was no absolute reversal of persistent visual loss; the trial was terminated by the National Eye Institute\[[@CR249]\]RCTIVIg 0.4 g/kg per day (Immunoglobulin SSI liquid; Statens Serum Institute, Copenhagen, Denmark), infused on days 0--2, and 1 to 2 months later (*n* = 34) vs placebo (*n* = 34)68 patients with recent visual accuracy loss; 34 patients received IVIg (of which 15 had multiple sclerosis), compared with 34 patients who received placebo (of which 8 patients had multiple sclerosis)No immediate or delayed effects were observed; there was no change in visual acuity; MRI findings and visual evoked potential resultsInflammatory pseudotumor of orbit\[[@CR250]\]Case reportIVIg 2 g/kg divided over 4 days1 patient with inflammatory pseudotumor of the orbit, resistant to systemic CS, and radiation therapyBoth clinical and radiographic improvement within daysBirdshot retinochoroiditis\[[@CR251]\]Case seriesIVIg 0.4 g/kg per day for 4 days; then 0.6 g/kg per day for 2 days, every 4 weeks37, of which 18 were followed upVisual acuity of 53% of patients\' eyes has increased by 2.6 ± 1.5; in 29% of patients, visual acuity remained stable, and in 18% of eyes VA have decrease\[[@CR29]\]Case seriesIVIg 1.6 g/kg every month for 6 months, followed by 1.2--1.6 g/kg every 6--8 weeks18 patientsIn patients with visual acuity of 20/30, there was increase in visual acuity in 53.8% of eyes and decrease of acuity in 7.7% while there was no change in the remaining eyesOrbital myositis\[[@CR252]\]Case reportIVIg (Venimmun) 0.3 g/kg per day for 3 days1 patient intolerant to CS treatment and poor clinical responseBoth clinical and tomographic resolution within 2 weeksRefractory uveitis\[[@CR253]\]Case seriesIVIg (Baxter Healthcare, Glendale, CA, USA), 0.5 g/kg per day for 3 days each month; median of 7.5 cycles10 patients with poor response to immunosuppression (some cases were idiopathic, others were secondary to sarcoidosis, Behcet, inflammatory bowel disease, and birdshot retinochoroiditis)50% sustained improvement of visual acuity, 20% have required a reduced doses of immunosuppressive therapy without disease progression; the patient with sarcoidosis had improved vision and reduced need for immunosuppression, although that effect was not sustained 4.5 months following treatment discontinuation; the Behcet patient showed marked improvement\[[@CR254]\]Case seriesIVIg, 1--2.5 g/kg per cycle over 3 days; cycles were repeated every 2--4 weeks initially and every 5 to 6 weeks after effect was observed; treatment time averaged at 16.8 months5 patients unresponsive to conventional therapy, of which 1 patient had juvenile idiopathic arthritis and 1 patient had psoriatic arthritis; 1 patient had retinal vasculitis and APLA; the other 2 cases were idiopathicIn 60% (2 idiopathic cases, 1 patient with vasculitis and APLA), treatment was effective in controlling inflammation, and visual acuity remained stable or improvedGraves\' ophthalmopathy\[[@CR255]\]Prospective nonrandomized35 patients were treated with IVIg and 27 with CS62 patients with Graves\' ophthalmopathy76% response in IVIg-treated patients compared to 66% in CS group, in a manner that was statistically insignificant; side effects were more common in patients receiving CS therapy\[[@CR256]\]RCT21 patients were treated with 6 cycles of 1 g/kg IVIg for 2 days every 3 weeks; 19 patients were treated with oral prednisolone (starting dose 100 mg/day)40 patientsNo marked difference between IVIg (62% response) and prednisolone (63% response); both groups had significantly improved proptosis, visual acuity, decrease of intraocular pressure, and decrease of eye muscle areaParaneoplastic visual loss\[[@CR257]\]Case series2 patients were treated with IVIg 0.4 mg/kg per day for 5 days; 1 patient received single-dose d/t treatment intolerance3 patients1st patient improved from distinguishing hand movement to 20/40 and 20/50 OS; improved visual fields2nd patient, no improvement3rd patient, improved visual field without change in visual acuity\[[@CR258]\]Case reportIVIg, as well as radiotherapy and surgical resection1 patient with melanoma-associated retinopathyImprovement in visual fields over 1 year of follow-up

Ophthalmic IgA bullous disease {#Sec70}
------------------------------

### Level of evidence C {#d29e6919}

Linear IgA bullous disease may affect the eye (in 67% of patients) and may present as chronic cicatrizing conjunctivitis. Systemic disease may be treated with systemic CS and dapsone. In poorly responsive patients, IVIg treatment may be used, although its use should be further investigated (*strength of recommendation IIa*).

Mucous membrane pemphigoid {#Sec71}
--------------------------

### Level of evidence C {#d29e6930}

Mucous membrane pemphigoid (MMP) may involve the eye. There is some evidence for the beneficial effect of IVIg in MMP that involves the eye. IVIg may provide more rapid control of symptoms and prevents remissions during long-term follow-up \[[@CR27], [@CR28]\]. This notion should be supported by larger randomized trials (*strength of recommendation IIa*).

Ocular Behcet's disease {#Sec72}
-----------------------

### Level of evidence C {#d29e6947}

There are some but limited data regarding the potential benefit of IVIg use in Behcet\'s disease. Further study is required. Nevertheless, IVIg should be carefully considered in patients resistant to conventional immunosuppressive therapy (*strength of recommendation IIa*).

Optic neuritis {#Sec73}
--------------

### Level of evidence A {#d29e6958}

The natural history of optic neuritis in multiple sclerosis patients is not altered by IVIg transfusion, neither clinically nor radiologically. Therefore, IVIg is not recommended in that setting (*strength of recommendation III*).

Inflammatory pseudotumor of orbit {#Sec74}
---------------------------------

### Level of evidence C {#d29e6969}

There is anecdotal evidence for the possible beneficial role of IVIg in the treatment of inflammatory pseudotumor of orbit (*strength of recommendation IIb*).

Birdshot retinochoroiditis {#Sec75}
--------------------------

### Level of evidence C {#d29e6980}

Birdshot retinochoroiditis is a rare inflammatory disease (bilateral autoimmune posterior uveitis of idiopathic origin). Without immunosuppressive treatment, a progressive visual deterioration will occurs in 80% of patients \[[@CR29]\]. There is supporting evidence for the use of IVIg, especially in patients unresponsive to other therapies (*strength of recommendation IIa*).

Orbital myositis {#Sec76}
----------------

### Level of evidence C {#d29e6994}

It is caused by inflammatory process of unknown etiology, which is confined to the orbit. There are very limited data on the effect of IVIg in patients with orbital myositis. Such treatment might be considered in symptomatic patients, resistant to other therapies (*strength of recommendation IIa*).

Refractory uveitis {#Sec77}
------------------

### Level of evidence C {#d29e7005}

Most cases of refractory uveitis (RU) are associated with autoimmune mechanisms. There are some data supporting the use of IVIg in resistant RU, although more research is required in order to establish clinical guidelines (strength of recommendation IIa).

Graves\' ophthalmopathy {#Sec78}
-----------------------

### Level of evidence B {#d29e7013}

It seems that IVIg is as efficient as CS in the treatment of Graves\' ophthalmopathy. Nevertheless, despite similar clinical response to treatment, IVIg was associated with fewer side effects and the study group showed more tolerance towards it. Therefore, we conclude that IVIg should be considered in CS intolerance (*strength of recommendation I*).

Paraneoplastic visual loss {#Sec79}
--------------------------

### Level of evidence C {#d29e7025}

There is limited evidence for the benefit of IVIg in cancer-associated retinopathy. Nevertheless, since spontaneous recovery usually does not occur, IVIg may be used in progressive visual compromise in addition to CS or plasmapheresis (*strength of recommendation IIb*; Table [8](#Tab8){ref-type="table"}). Table 8The use of intravenous immunoglobulins in kidney diseasesDiseaseRef.Study designIntervention including dose and IVIg preparation usedNumber of patientsResults/responseMembranous nephropathy\[[@CR259]\]Retrospective uncontrolled trialIVIg 0.4 g/kg every 21 days (mean duration of treatment was 15 months equal to 21 cycles)13 adult patients (8 males, 5 females) with primary membranous glomerulonephritis5 patients had complete remission5 patients had partial remission3 patients no clinical remission but presented marked reduction in proteinuria\[[@CR260]\]Case seriesIVIg 0.4 g/kg per day for 3 days every 21 days (3 courses), then once every 3 weeks for 10 months9 patients with biopsy-confirmed idiopathic membranous nephropathy5 patients with normal renal function: 4 had complete remission, 1 had partial remission4 patients with moderate renal insufficiency: 1 had complete remission, 2 had partial remission, 1 had no response\[[@CR261]\]Retrospective analysisIVIg 0.1--0.15 g/kg per day for 6 days, 1--3 courses86 with primary membranous glomerulonephritis30 patients were treated with IVIg: 13 patients had complete remission; 11 patients had partial remission; 3 patients had continued nephrotic state with renal dysfunction; 3 patients reached end-stage renal diseaseIgA nephropathy\[[@CR262]\]Single-arm, nonrandomized studyIVIg 2 g/kg monthly for 6 months14 patients with progressive IgA nephropathy6 patients received IVIg; the mean loss of renal function and proteinuria were significantly reduced in the IVIg group (*p* = 0.024, *p* = 0.015, respectively)\[[@CR62]\]Open prospective cohort studyIVIg 2 g/kg per month for 3 months followed by IMIg for another 6 months11 patients with moderate IgA nephropathyProteinuria, glomerular filtration rate, and histologic index of activity were significantly decreasedBK-virus-associated nephropathy in renal allograft recipients\[[@CR263]\]Case seriesIVIg 2 g/kg over 2--5 days + immunosuppression8 renal allograft recipients with BK-virus-associated nephropathy88% of the patients were dialysis free and had stable renal function after follow-up of 15 months\[[@CR264]\]Case reportIVIg 0.6 g/kg, 5 doses repeated every 4--6 weeksA pediatric renal transplant patient recipients with BK-virus-associated nephropathyStabilized renal function, reduced viral load, and resolved histological findings were noted after IVIg treatmentANCA-associated rapidly progressive glomerulonephritis (RPGN)\[[@CR265]\]Case seriesIVIg 0.4 g/kg per day for 5 days + CS ± CP after IVIgTwelve patients with MPO-ANCA-associated RPGN (7 men, 5 women)After IVIg treatment, a significant reduction was noted in white blood cell count (*p* \< 0.05), in C-reactive protein values (*p* \< 0.001), in Birmingham vasculitis; Activity Score (*p* \< 0.001) and in the rate of change in 1/Cre (*p* \< 0.05)\[[@CR57]\]Case seriesIVIg 0.4 g/kg per day for 5 days + immunosuppressive therapy30 patients with MPO-ANCA-associated RPGN (male 17, female 13)After IVIg, significant reduction in CRP (*p* \< 0.001), improvement in serum creatinine in 63% of patients; at 3 months, disease activity was completely reduced; at 6 months, renal survival rate was 92% and life survival was 93%\[[@CR266]\]Case reportIVIg (Omr-IgG-am5%IV) 0.5 g/kg per day for 4 days after immunosuppressive therapyA 68 year-old woman with RPGNSignificant improvement in renal function after IVIg treatment\[[@CR267]\]Case reportsIVIgA 66-year-old male and a 14-year-old boy with MPO-ANCA-associated RPGNSignificant improvement in both patients including renal function after IVIg treatmentRenal transplant rejection\[[@CR268]\]Prospective pilot trialIVIg 1 g/kg per dose every week for 4 weeks + rituximab 1 week after last IVIg infusion6 pediatric renal transplant recipients with chronic antibody-mediated rejection4/6 responded to IVIg with significant improvement in glomerular filtration rate (*p* \< 0.05); 2/6 no response\[[@CR269]\]Case reportIVIg 0.5 g/kg every other day for 4 cycles + rituximab + plasmapheresisA 46-year-old female renal transplant recipient with antibody-mediated rejectionImprovement in renal function\[[@CR270]\]Case reportIVIg 0.15 g/kg within 72 h of transplantation, and 0.1 g/kg every 2 weeks for 4 doses, followed by monthly infusions for 2 doses + plasmapheresis + monoclonal anti-T lymphocyte antibody therapyA 14-year-old renal transplant recipient with antibody-mediated rejectionImprovement in renal function and reverse of Ab-mediated rejection\[[@CR271]\]Case seriesIVIg 2 g/kg7 renal transplant recipient with antibody-mediated rejectionIVIg-induced reversion of acute rejection in all patients and reduced donor-specific anti-HLA alloantibody levelsLupus nephritis\[[@CR272]\]RCTDuring 18 months, 5 received IVIg 0.4 g/kg once a month, 9 continued CP14 patients with proliferative lupus nephritisTreatment with IVIg as maintenance therapy was safe and effective as CP\[[@CR273]\]Case seriesIVIg, 0.4 g/kg for 5 days, of ISIVEN (Istituto Sierovaccinogeno Italiano I.S.I.S.p.A, Italy).7 lupus nephritis patients who failed to respond to at least PD and CPAll patients had a beneficial response to IVIg; all had significant decrease in proteinuria\[[@CR274]\]Case reportIVIg 2.8 g/kg, one doseA 39 year-old female SLE patient with lupus serositis and nephritisClinical improvement and significant decrease in proteinuria.\[[@CR275]\]Case reportIVIg 12.5 g/day for 5 successive days after CS and plasmapheresis treatmentA 34-year-old Japanese female patient with rapidly progressive lupus nephritis associated with anti-MPO antibodiesSignificant improvement of renal function after IVIg treatment

Lupus nephritis {#Sec80}
---------------

### Level of evidence B {#d29e7493}

A few case reports and a single RCT clearly indicate the efficacy of IVIg in the treatment of lupus nephritis. In all cases, patients had a beneficial response to IVIg and a significant improvement of renal function was noted. Therefore, IVIg is recommended as an alternative treatment in lupus nephritis or in cases that conventional immunosuppressive treatment fails (*strength of recommendation I*).

Renal transplant rejection {#Sec81}
--------------------------

### Level of evidence C {#d29e7504}

Although evidence for the use of IVIg in renal transplant rejection is limited to case reports and case series results showed that IVIg may be effective for treating acute or chronic renal transplant rejection. IVIg may improve renal function and reverse Ab-mediated rejection. IVIg may be considered among the treatment options generally together with immunosuppressive therapy (*strength of recommendation I*).

ANCA-associated rapidly progressive glomerulonephritis (RPGN) {#Sec82}
-------------------------------------------------------------

### Level of evidence C {#d29e7515}

There is weak evidence indicating significant benefit from the use of IVIg in antineutrophil cytoplasmic antibody (ANCA)-associated RPGN. Several case series and case reports showed that IVIg may improve renal function and therefore is recommended as a potential therapy for ANCA-associated RPGN (*strength of recommendation I*).

BK-virus-associated nephropathy in renal allograft recipients {#Sec83}
-------------------------------------------------------------

### Level of evidence C {#d29e7526}

The use of IVIg in BK-virus-associated nephropathy in renal allograft recipient is limited only in a few case reports. Nevertheless, in these cases, IVIg showed significant efficacy and with concomitant reduction of immunosuppression it may be considered as one of the treatment options in this disease (*strength of recommendation I*).

IgA nephropathy {#Sec84}
---------------

### Level of evidence B {#d29e7537}

Results coming from a single-arm nonrandomized study and a prospective cohort study showed that IVIg may be effective in treating severe IgA nephropathy and therefore it may be considered as a possible treatment option. However, RCTs are needed to confirm this efficacy (*strength of recommendation I*).

Membranous nephropathy {#Sec85}
----------------------

The efficacy of IVIg in membranous nephropathy was studied in few retrospective trials and a case series. Results from these studies indicate that IVIg may be effective in induction of remission. Although there is no strong evidence, IVIg may be considered as an additional option in treatment of membranous nephropathy (strength of level of evidence C; *recommendation I*; Table [9](#Tab9){ref-type="table"}). Table 9The use of intravenous immunoglobulins in dermatologic diseasesResults/responseNumber of patientsIntervention including dose and IVIg preparation usedStudy designRef.Disease21/21 reached sustained remission; mean time to clinical response 4.5 months; maintenance therapy for a mean 22.7 months; compared to pretreatment period the study subjects received a lower dosage of CS and immune-suppressive therapy, had fewer side effects, recurrences, and relapses, needed fewer hospital admissions and days of hospital stay (*p* \< 0.001), and reported better quality of life (*p* \< 0.0001)21 patients with severe pemphigus vulgaris unresponsive to corticosteroid and immune-suppressive agentsMonotherapy 2 g/kg given in 3 days in 4-week interval until complete healing, afterwards after 6, 8, 10, 12, 14, and 16 weeks if patient is disease free; end point---disease free with a 16-week interval between the 2 infusion cycles; adjunctive to other systemic therapy, not effective in the beginning of trialUncontrolled trial\[[@CR276]\]Pemphigus vulgaris10/12 (83%) responded, 6/12 (50%) had complete remission and 4/12 (33%) partial response; 72% decline of pemphigus antibody levels and steroid-sparing effect12 patients with severe unresponsive pemphigus vulgarisIVIg for 6 months as adjuvant to immune-modulating therapyUncontrolled trial\[[@CR277]\]No new lesions and 72% decline of pemphigus antibodies levels after 1 week, 80% reduction of extent of existing lesions in 5/6 patients after 2 weeks, 41% reduction of steroid doses after 3 weeks6 patients with active pemphigus vulgaris, unresponsive to at least 2 months of CS therapyIVIg 2 g/kg in 5-day cycles (as 5% solution, Venoglobulin S; Alpha Therapeutics Co, LA, CA, USA) concurrent with CS and cyclophosphamide 100--150 mg/dayUncontrolled trial\[[@CR278]\]Significant reduction of total PD dose (*p* = 0.004), duration of PD therapy (*p* = 0.003), and number of relapses (*p* \< 0.001); CS was discontinued over a mean period of 4.3 months15 patients with steroid-dependent pemphigus vulgaris, mean follow-up of 6.2 yearsIVIg 1 to 2 g/kg given in 3 doses on 3 consecutive days as a 4- to 5-h infusion at a frequency of every 3 to 4 weeks adjunctive to CS (no other immunosuppressive therapy was allowed); intervals were increased to 6, 8, 10, 12, 14, and 16 weeks, if clinical response was achievedRetrospective analysis\[[@CR279]\]38/39 on adjunctive therapy improved; in monotherapy group, no change in 2 patients, worth in 142 patients with pemphigus vulgarisIVIg 2 g/kg per month in 37 patients; 0.3 g/kg per day in 4 patients, 0.25 g/kg per day in 1 patient; Sandoglobulin® in 10, Puimmun® in1, NA in 31 adjunctive in 39, monotherapy in 3Review of published case reports\[[@CR238]\]6/7 did not respond; 1/7 had partial response with \>50% improvement (but died 1 month after IVIg cycle of pneumonitis)7 patients with pemphigus vulgarisAs adjunctive therapy in the dose of 2 g/kg per cycle, 4/7 patients received Venoglobulin®; other 3 patients received Gammagard/Gammar P.I.V/Gamimune; mean duration of treatment was 7 monthsCase series\[[@CR280]\]11/11 had effective clinical response in mean of 5.3 months, clinical remission for a mean period of 18.6 months after discontinuation of IVIg; After IVIg, the study subjects received a lower dosage of CS (*p* = 0.001), had fewer side effects (*p* = 0.002), recurrences, and relapses (*p* = 0.001), had fewer hospital admissions and days of hospital stay (*p* \< 0.01), and had better quality of life (*p* = 0.001) compared to pretreatment period11 patients with refractory pemphigus foliaceusIVIg 2 g/kg given over 3 days in 4-week interval until complete healing, afterwards after 6, 8, 10, 12, 14, and 16 weeks if patient is disease free; end point---disease free with a 16-week interval between the 2 infusion cycles; adjunctive to other systemic therapy, previously not effectiveUncontrolled trial\[[@CR281]\]Pemphigus foliaceus8/8 significant reduction of antidesmoglein antibodies after 4 months of treatment (*p* NA), nondetectable titers after 13 months, serological remission after additional observation period of 5 months8 patients with severe pemphigus foliaceusIVIgUncontrolled trial\[[@CR282]\]CS gradually discontinued over a mean period of 2.8 mo, with resulting reduction of PD total dose (*p* = 0.005), total duration of PD treatment (*p* = 0.02) and number of relapses (*p* = 0.002) according to pre-IVIg therapy.7 steroid dependent pemphigus foliaceus patients.In the beginning of the trial adjunctive to CS and as monotherapy afterwards.Uncontrolled trial\[[@CR283]\]All improved28 patients with pemphigus foliaceusAdjunctive IVIg 1 to 2 g/kg per month, 0.27 g/kg per month in 1, continued for several weeks to more than 5 monthsReview of published case reports\[[@CR238]\]15/15 clinical response within mean of 2.9 months; all patients demonstrated fewer hospital admissions, fewer relapses and recurrences, significant steroid-sparing effect (were tapered over a mean period of 3.3 months), and quality of life improvement compared to pre-IVIg therapy (*p* \< 0.0001)15 patients with recurrent bullous pemphigoid despite oral PD and systemic immune-modulating treatmentIVIg 2 g/kg over 3 days by 4--5-h infusion adjunctive to oral PD, given every 4 weeks, until clinical stabilization; intervals were gradually increased to 6, 8, 10, 12, 14, and 16 weeks (mean number of cycles 14.7)Uncontrolled trial\[[@CR284]\]Bullous pemphigoid12/17 (70%) improved; 5/17 (30%) had no change; in some patients, high-dose IVIg had systemic steroid-sparing effect; the lack of response was observed in low-dose or single-effusion cases; early treatment, multiple treatment cycles, and concomitant immunosuppressive treatment led to longer and more sustained remissions17 patients with severe bullous pemphigoid15 patients received high-dose IVIg 2 g/kg per month for 1 month (12 patients) to 3 months (1 patient); 2 patients received 0.1 and 0.3 g/kg per day for 5 days (low dose), 10 patients as monotherapy and 8 adjunctive to immunosuppressive therapyReview of published case reports\[[@CR285]\]1/3 complete response after 4 cycles, maintained with 5 additional cycles; 2 patients had no response3 patients with bullous pemphigoidAdjunctive therapy with 2 g/kg per month of Venoglobulin® in 2 and Carimune® in 1 of 3 patients for mean 7 monthsCase report\[[@CR280]\]19/22 improved on adjunctive therapy, 8/12 improved on monotherapy within 2 weeks--4 months34 patients with bullous pemphigoidAdjunctive 22, monotherapy in 12 2 g/kg per month in 32 patients, 0.1 g/kg per day for 5 days and 0.3 g/kg per day for 5 days in 2 patients; Venoglobulin® in 11, Sandoglobulin® in 4, NA in 23 continued up to 14 monthsReview of published case reports\[[@CR238]\]Clinical response in 7/7 patients, treated with IVIg, after a mean period of 4.5 months, sustained remission after a mean treatment period of 26.9 months, improvement of quality of life after IVIg therapy (*p* \< 0.001); reduction of antibody titers in both groups (*p* = 0.015), but faster in IVIg group (*p* = 0.03)7 patients (mean age of onset 55.5) on IVIg monotherapy vs. 7 random patients (mean age of onset 55) with severe (+3) oral pemphigoid; treatment period 12 monthsMonotherapy with 1 to 2 g/kg per month IVIg vs. conventional immunosuppressive treatment (PD and dapsone or AZA or MTX or tacrolimus or CP); adjunctive local treatment with sublesional injections of triamcinolone acetonide (proven not to be systemically absorbed by serum cortisol levels) was given to patients in both groupsControlled trial\[[@CR286]\]Mucous membrane pemphigoidSignificant improvement, reduction of relapses, duration and total dosage of corticosteroid therapy and quality of life after IVIg (*p* NA)15 patients with severe mucous membrane pemphigoidIVIg 1 to 2 g/kg per monthUncontrolled trial\[[@CR283]\]All patients improved within 2--6 months on combination therapy and within 4--6 months on monotherapy, steroid-sparing effect in adjunctive therapy group43 patients with mucous membrane pemphigoidIVIg 1--3 g/kg over 3--5 days for 2--4-weeks; adjunctive/monotherapy 28/15.Review of published case reports\[[@CR238]\]Improved 3/3 on adjunctive and 2/3 monotherapy, 1/1 UV protection7 patients with epidermolysis bullosa acquisita 16--59 years old, all malesIVIg 0.4 g/kg per day for 5 days, 2--6 weeks (4), 2 g/kg per day 2 weeks (1), 0.04 g/kg per day for 5 days 3--4 weeks (1), 1.2 g/kg per month (1) Polyglobulin® in 1, Sandoglobulin® in 3, NA 3; adjunctive therapy 3, monotherapy 3, 1 UV protection for 1--4 monthsReview of published case reports\[[@CR238]\]Epidermolysis bullosa acquisitaAll improved3 patients 45--67 years old with linear IgA diseaseSandoglobulin® 0.4 g/kg per day over 5 days in 1 patient; 2 patients received 4 g/kg per month regiment (preparation NA); 2 patients received CS as additional treatmentReview of published case reports\[[@CR238]\]Linear IgA diseaseComplete response after 5 cycles of IVIg (3.5 months), IVIg continued for additional 10.5 months1-week-old newborn with linear IgA diseaseAdjunctive therapy with Venoglobulin® 1 g/kg every 2--4 weeks for 14 monthsCase report\[[@CR280]\]Steroid-sparing effect, maintained with cyclosporine and low-dose prednisolone; cyclosporine was stopped 16 months after delivery17-year-old female with pemphigoid gestationis, developed at 20 weeks gestation in her 1st pregnancy2 g/kg per month for 2 months adjunctive to CSCase report\[[@CR287]\]Pemphigoid gestationisObjective response in all patients within a mean of 2 days, skin healing within 8.3 days, slow healing in patients with underlying diseases, an overall survival rate of 100%12 patients with SJS (mean age 44)Commercially available IVIg at a mean dose of 0.6 g/kg per day for an average of 4 days as monotherapyRetrospective multicenter study\[[@CR288]\]Stevens--Johnson syndromeThe average duration of fever was 8 days in IVIg-treated vs. 14 in non-IVIg-treated group (*p* = 0.06); the mean stay in hospital was 12 days in IVIg-treated vs.15 days in non-IVIg-treated group (*p* = 0.5)Total of 12 patients (mean age 6 years), 7 IVIg-treated and 5 non-IVIg-treatedIVIg as single infusion at 1.5--2.0 g/kg given on an average of 3 hospital daysRetrospective series report\[[@CR289]\]No mortality, arrest of disease progression in 1--5 days (mean 2.83), re-epithelialization in a mean of 7.33 days (range 5--13); the average duration of hospital stay was 12.5 days12 patients (average age 27.2 years, 4 children 7--12 years old); the average affected body area was 57.5%IVIg 0.5--1.0 g/kg per day for 4--5 days adjunctive to standard care protocol, infusion started on average 1.58 daysUncontrolled trial\[[@CR290]\]Toxic epidermal necrolysis90% of patients survived; one patient with previous history of severe heart disease died as a result of cardiac arrest during the first day of treatment10 patients with TEN with predicted mortality rate 35% according to SCORTENIVIg 0.4 g/kg per day for 5 days started within 3 days from the onset of TENProspective single center uncontrolled\[[@CR291]\]Progression of epidermal detachment in 22/34, more deaths than predicted by prognostic SCORTEN score (11 (32%) instead of 8.2 (24%)), most deaths in elderly with renal impairment34 patients with a mean of 4.3 days after onset of SJS (*n* = 9), SJS/TEN (*n* = 5), TEN (*n* = 20)IVIg 2 g/kg within 2--5 days (30 patients treated with Tegeline (Laboratoire francais du Fractionnement et des Biotechnologies, France), 2 with Sandoglobulin® (Novartis, France), 2 with Gammagard ® (Baxter, France), only Gammagard did not include sucrose)Uncontrolled trial\[[@CR292]\]Mortality rate was 20% in IVIg-treated patients vs. 50% in non-IVIg group (overall mortality of 33%)9 patients with TEN---all treated with CS; 5/9 received IVIg as adjunctive therapyIVIg 0.75--1 g/kg per day for 3 days adjunctive to intravenous prednisolone 0.25--0.5 g/day for 1--3 daysRetrospective series report\[[@CR293]\]All survived3 patients with 30--70% epidermal detachmentIVIg 0.5 g/kg per day for 4 days (2 patients), 1 patient was switched after 24 h to 0.6 g/kg per day for 2 days due to further deteriorationCase series\[[@CR294]\]7/7 survived, a cessation of blistering in 7/7 patients within an average of 2 days; in published cases, time to objective response could be ascertained in 20 patients: cessation of blistering after an average of 2.5 days; patients with concomitant CS treatment were noted to have a longer time to objective response7 pediatric patients with SJS and 28 published pediatric cases of SJS (12), SJS/TEN (5), and TEN (11) treated with IVIg7 patients IVIg (Gamimune) in an average dose of 2 g/kg over 4 days (on days 1, 2, 4, and 6) initiated an average of 2.7 days after onset, in 5 cases adjunctive to CS in 28 published cases, an average total dose of 2.5 g/kg initiated 3.75 days after blister onsetRetrospective case series and review of published case reports\[[@CR295]\]Time to objective response was 2.3 ± 1.2 days; duration of IVIg treatment was 4 ± 0.9 days; objective response rate was 90%; survival rate was 88%; time to complete healing was 15 ± 9.5 days; the odds of survival decreased per year of life (*p* = 0.02) and increasing epidermal detachment (*p* = 0.03); more underlying disease in the group of nonsurvivors (*p* = 0.03)48 patients with TEN (mean age 44), with skin detachment in 44.8 ± 22.5% and mucous membrane involvement in 91.7% of casesCommercially available IVIg at mean dose of 0.7 g/kg per day for a mean of 4 days given as monotherapy 7.3 ± 6 days from onset of TENRetrospective multicenter\[[@CR296]\]83% reduction of mortality (1 patient died instead of 5.8 expected based on SCORTEN)16 patients with TENIVIg for 4 days (15 patients 1 g/kg per day and 1 patient 0.4 g/kg per day); 2 patients received IVIg without sucroseRetrospective series report\[[@CR297]\]The average time to arrest of progression was 2.1 days; complete re-epithelialization was 8.1 days and length of hospitalization 13.6 days; no mortality8 pediatric patients with TEN with mean surface involvement of 67%Monotherapy of IVIg 0.5--0.75 g/kg per day for 4 consecutive days, started with average delay of 3.2 days after blisters onsetRetrospective series report\[[@CR298]\]No difference in length of stay, mechanical ventilation, severity of inflammatory response or incidence of sepsis, wound progression, time to healing, and mortality16 TEN patients with initial rash involving 65 ± 29%, treated with IVIg vs. 16 patients with TEN initial rash involving 65 ± 27% not treated with IVIgIVIg (Gamimune® N, Bayer Inc., Toronto, CA) 0.2 to 0.7 g/kg per day according to discretion of attending physician on duty, as 5% or 10% solution according to availability, for 4 ± 1 dayRetrospective\[[@CR299]\]No difference of SCORAD index and in global evaluation of disease severity by patients at day 3010 adult patients (mean age 28) with sever atopic dermatitisIVIg 1 g/kg per day (Sandoglobulin®, Sandoz, France) immediate or delayed by 1 month (meanwhile intensive therapy with emollients and topical CS (limited to class II 60 g/month)), for 2 days in 8-h infusion, as monotherapyRC evaluator-blinded trial\[[@CR300]\]Atopic dermatitisImprovement in skin score (mEASI) was apparent in responders (4/6 patients) from 2 to 3 months and continued to improve over a 6-month period; after 7 months, there was a significant reduction of the overall mEASI; CD69-expressing T cells decreased to 60% from baseline; no change of TNF-a and IFN-g6 adult patients with severe stable atopic dermatitisFlebogamma® 5% 2 g/kg per month given in 2--5 days for 6 months as adjunctive treatment, followed for 3 monthsOpen, single center, prospective\[[@CR301]\]3/3 patients improved skin scores, allowing reduction of steroid dose3 adult patients with severe atopic dermatitis and steroid-related side effectsAlphaglobin® (Grifols, UK) or Sandoglobulin ® (Novartis, UK) 2 g/kg per month in 3--5 days adjunctive to CS Aza, HxcCase report\[[@CR302]\]9/10 were available for analysis: 6/9 showed slight improvement of skin lesions; 2/9 were unchanged and 1/9 worsened; there were no steroid-sparing effect, change in mean IgE, lymphocyte response to PHA, Candida, tetanus, and anti-CD3 antibody, and change in RAST positivity to negativity10 patients (7--64 years old): 1 patient with hyper-IgE syndrome and 9 patients with atopic dermatitisAdjunctive to CS in 6/10 Venoglobulin® I (10%) 2 g/kg per month for 7 monthsOpen, single center\[[@CR303], [@CR304]\]9/10 patients less than 6 years old improved on monotherapy; 1 patient with WAS failed to improve after 1 treatment cycle; 17/22 adults received adjunctive therapy; 10/17 (59%) improved; the longest time to response was 3--4 months32 patients (8 months to 64 years old) with atopic dermatitis2 g/kg per month for 1 to 11 cycles, 1 patient with WAS 1 g/kg per month for 1 month; 14/32 patients received IVIg as monotherapy, 5 patients Bayer Biological Co., 6 patients Flebogamma®, 10 patients Venoglobulin I ®, 3 patients Sandoglobulin®/Alphaglobulin®, 8 patients preparation NAReview of published case reports\[[@CR304]\]9 of 10 patients responded: 3 patients with complete remission sustained 3 years later; 2 patients with temporary complete remission; 4 patients improved subsequent to treatment; total urticaria activity score assessed by physician and by patient with the use of visual analog score at 2 and 6 weeks improved significantly (*p* \< 0.01) without significant change of the positivity of autologous serum injection test10 patients with severe chronic autoimmune urticaria0.4 g/kg per day for 5 days as 3% solution in normal saline on the first day, followed by a 6% solution on the succeeding 4 days (Sandoglobulin®, Novartis, UK); sympatientomatic treatment with cetirizine 20 mg/day was taken by all patientsCase series\[[@CR305]\]Chronic urticariaAfter the 1st application of IVIg, urticaria score was reduced to 1, maintained with repeated administrations of IVIg in intervals of 4 weeksA 63-year-old woman with a 2-year history of chronic urticaria with urticaria score of 4/8 despite H1-and H2-blockersLow-dose IVIg 0.2 g/kg every 4 weeks adjunctive to standard antihistamine therapyCase report\[[@CR306]\]95% resolution over 3.5 months without concomitant therapyA 28-year-old female with 41-month history of severe chronic urticaria1 cycle of Venoglobulin® 2 g/kg in 5 days as monotherapyCase report\[[@CR280]\]5 of 8 responded: 3 remission (2 after one and 1 after 3 cycles); 2 patients improved; responders improved with 3 or fewer infusions; 3 patients failed to improve after 2--6 cycles of IVIg; ASST was not a predictor of response to IVIg8 adult patients with steroid-dependent refractory delayed pressure urticaria (concomitant with chronic urticaria 8/8, angioedema 4/8, cholinergic urticaria 1, and dermographism 1)2 g/kg per month (Scottish National Blood Transfusion Service) over 2 to 3 days, followed by antihistamines and CSUncontrolled trial\[[@CR307]\]Delayed pressure urticariaAfter 3 cycles tolerated visible light and 15 min of intense solar exposure, SU has disappeared after 1 year55-year-old woman suffered from resistant solar urticaria for 3 yearsIVIgCase report\[[@CR308]\]Solar urticariaOptimal improvement with combination of IVIg, antihistamines, and PUVAA female patient with resistant solar urticariaIVIg 2.5 g/kg over 3 daysCase report\[[@CR309]\]Taper off of CS and prolonged remission; recurrence and remission of symptoms were associated with changes of IVIg lot and sourceA 54-year-old manIVIg 0.4 g/kg every 3 weeks (Panglobulin® or Gamimune N® according to availability) adjunctive to CSCase report\[[@CR310]\]Angioedema with hypereosinophilia syndrome2 patients experienced dramatic improvement in both their joints and skin and a fall in inflammatory markers; 1 patient had improvement in arthritis but little change in skin involvement3 patients with treatment-resistant psoriasis and psoriatic arthritisIVIg (Octagam®, Octapharma, Coventry, UK) 2 g/kg over 3 to 4 days adjunctive to conventional treatment; in 2 cases, improvement was sustained with additional cycles of IVIg; in 1 case, information is not availableCase series\[[@CR311]\]Psoriasis7 of 10 patients demonstrated clearance of lesions; in 6/7 of cases, the efficacy maintained with repeat IVIg infusions10 patients with severe refractory pyoderma gangrenosumIVIg 2 g/kg per month in 3 days, 9/10 in conjunction with CS and MMF and/or cyclosporin; IVIg was stopped after 2 to 3 cycles in case of ineffectivenessCase series\[[@CR312]\]Pyoderma gangrenosumStabilization of pyoderma gangrenosum and steroid-sparing effect in both patientsCase 1 with a 6-year and case 2 with a 3-year history of multidrug-resistant pyoderma gangrenosumIVIg 2 g/kg per month for 6 months adjunctive to CSCase report\[[@CR313]\]Improvement of range of joints motion and laxity of skin after 1 month but no further improvement after the 2nd and the 3rd cycles of IVIgA 61-year-old male with a 4-month history of NFDIVIg 2 g/kg in 5 days for 3 monthsCase report\[[@CR314]\]Nephrogenic fibrosing dermopathyClinical improvement in all patients after 2--9 months with reduction of skin thickness by US evaluation (4/7), reduction of mucopolysaccharide skin content (3/7), disappearance of lymphocytic skin infiltration and IgG deposition (2/7)7 patients affected by Grave\'s ophthalmopathy and pretibial myxedemaIVIg Endoglobulin® 2 g/kg every 3 weeks as monotherapyCase series\[[@CR315]\]Pretibial myxedema8 patients had complete (2) or partial (6) response, but in all the effect was transient, requiring reinfusion and maintenance therapy10 patients with scleromyxedema---8 cases proven by skin biopsy, 2 had inconclusive biopsy results but had classic clinical findings and a characteristic gammopathyIVIg in dose 0.4--1.0 g/kg per day for 2--5 days for a total 2 g/kg every month for 6 months as monotherapy after failure of other treatment modalitiesCase series\[[@CR316]\]Arndt--Gottron scleromyxedemaAll patients had cutaneous improvement as well as improvement in ureteral stricture, vocal strength, and dysphagia3 patients with scleromyxedemaIVIg 0.4 g/kg per day for 5 days every 5 weeks (Gammagard; Baxter Healthcare Corp, Hyland Immuno, Glendale, CA, USA)Case report\[[@CR317]\]First patient had significant reduction in skin scores (36/60 to 11/60) for 1 year only; second had a dramatic sustained response with continued Tx (interval subsequently increased to 10 weeks)2 patients with scleromyxedema and severe skin diseaseIVIg 0.4 g/kg per day for 5 days, monthlyCase report\[[@CR318]\]Improvement after the first treatment, continuous skin softening and reduction of induration, sustained response to treatment after 20 coursesA 48-year-old female with long-standing scleromyxedema unresponsive to high-dose CS and immunosuppressive (CP, melphalan) treatmentIVIg 2 g/kg in 2 days (Intratect®; Biotest, Dreieich, Germany) every 4 weeks, adjunctive to PD 10 mg/dayCase report\[[@CR319]\]Progressive clinical improvement over several months allowing discontinuation of PD but rapid deterioration afterwards with lethal CVA despite reinstating PD and CPAn 81-year-old female with scleromyxedema and IDDMIVIg (Gamimune N, 10%, Bayer) 1.5 g/kg (dose reduced due to CHF) every 4 weeks and oral PD 30 mg/dayCase report\[[@CR320]\]A positive response after 2 cyclesAn 82-year-old female with a 12-year history of scleromyxedema unresponsive to various preceding therapiesVenimmun® N (ZLB Behring, Germany) 0.5 g/kg for 5 days at 4-week intervals as monotherapyCase report\[[@CR321]\]Marked clinical improvement, maintained with repeated IVIg infusionsA 56-year-old woman with scleromyxedemaIVIg (Sandoglobulin®) 2 g/kg over 5 days as monotherapyCase report\[[@CR322]\]Complete clearance of skin lesions, sustained effect after 1 year without treatmentA 47-year-old female with 8-year history of tumorous variant of scleromyxedema and a history of ineffectiveness of melphalan and PD therapy5 courses of IVIg 0.3 g/kg for 5 days every 4 weeks adjunctive to melphalan 4--2 g/day and PD 30--10 mg/day, 5 additional cycles as monotherapy 1 year laterCase report\[[@CR323]\]Improvement in all but relapse in 1 patient, 2 weeks to 6 months for full response, most needing 6--8 weekly cycles10 patients, 30--79 years old with scleromyxedemaIVIg 2 g/kg per month given over 5 days; Octagam® (2 patients), Sandoglobulin® (3 patients), Gammagard ®SD (1 patient), unknown (2patients); adjunctive to PD (2 patients) and thalidomide (1 patient) or as monotherapy (7 patients)Review of published case reports\[[@CR324]\]Regrowth of eyelashes, eyebrows, and body and scalp hair after second dose, significant hair re-growth with 5--6 cm of scalp hair8-year-old girl with CVID and alopecia universalisIVIg 0.4 g/kg every 4 weeksCase report\[[@CR325]\]Alopecia universalis

Autoimmune blistering diseases {#Sec86}
==============================

Pemphigus vulgaris {#Sec87}
------------------

### Level of evidence B {#d29e8892}

There is some evidence that IVIg have steroid-sparing effect and may be effective as monotherapy and/or adjunctive therapy in patients with previously severe unresponsive pemphigus vulgaris (*strength of recommendation IIa*).

Pemphigus foliaceus {#Sec88}
-------------------

### Level of evidence C {#d29e8903}

Adjunctive to standard immunotherapy treatment with IVIg may cause improvement in clinical course and may have steroid-sparing effect in previously steroid-dependent patients with refractory pemphigus foliaceus (*strength of recommendation IIa*).

Bullous pemphigoid {#Sec89}
------------------

### Level of evidence C {#d29e8914}

In some severe cases of bullous pemphigoid, IVIg was found to be effective as monotherapy and adjunctive therapy as well; it had steroid-sparing effect and led to improvement of quality of life (*strength of recommendation IIa*).

Mucous membrane pemphigoid {#Sec90}
--------------------------

### Level of evidence C {#d29e8925}

There is some evidence that IVIg monotherapy may be at least as effective as standard immunosuppressive treatment and lead to quick therapy response and better quality of life (*strength of recommendation IIa*).

Epidermolysis bullosa acquisita, linear IgA disease, pemphigoid gestationis {#Sec91}
---------------------------------------------------------------------------

### Level of evidence C {#d29e8936}

The sparse data of positive effect of IVIg on severe cases of epidermolysis bullosa acquisita, linear IgA disease, and pemphigoid gestationis were published (*strength of recommendation IIa*).

### Summary {#d29e8944}

In autoimmune blistering diseases, the treatment with IVIg may be effective and has to be implicated in cases with severe disease, resistant to conventional therapy or those who experienced severe complications of such therapy.

Other immune-mediated dermatoses {#Sec92}
================================

Stevens--Johnson syndrome and toxic epidermal necrolysis {#Sec93}
--------------------------------------------------------

### Level of evidence C {#d29e8955}

The randomized studies have not been performed and the current knowledge about effectiveness of IVIg in SJS and TEN is based on results of multiple prospective noncontrolled studies, retrospective case series, and case reports. The data are limited and inconclusive (*strength of recommendation IIb*).

Atopic dermatitis {#Sec94}
-----------------

### Level of evidence B {#d29e8966}

The current data based on single, randomized, controlled, and evaluator-blinded trial and number of prospective noncontrolled studies suggest that IVIg may be effective as monotherapy in pediatric patients and as adjunctive therapy in adults. However, in view of the low-cost effectiveness of IVIg, this treatment should be used in cases of severe disabling atopic dermatitis (*strength of recommendation IIa*).

Urticaria {#Sec95}
---------

### Level of evidence C {#d29e8977}

A number of case reports and case series describe the beneficial effect of IVIg in chronic idiopathic and autoimmune urticaria, but randomized controlled studies are still lacking. The use of IVIg has to be limited to severe unresponsive cases of chronic urticaria or in case of severe complications of conventional treatment (*strength of recommendation IIa*).

Psoriasis {#Sec96}
---------

### Level of evidence C {#d29e8988}

Only three cases of severe resistant psoriasis with psoriatic arthritis responsive to treatment with high-dose immunoglobulin were reported. We conclude that there is now evidence of effectiveness of IVIg in psoriasis (*strength of recommendation IIb*).

Pyoderma gangrenosum {#Sec97}
--------------------

### Level of evidence C {#d29e8999}

IVIg was successfully used in few cases of previously unresponsive pyoderma gangrenosum, but its systematic use cannot be recommended (*strength of recommendation IIa*).

Miscellaneous dermatoses {#Sec98}
------------------------

### Level of evidence C {#d29e9010}

Several case reports and case series showed IVIg to be effective for nephrogenic fibrosing dermopathy, pretibial myxedema, and Arndt--Gottron scleromyxedema, but still well-controlled studies are lacking. We suppose that IVIg can be used in severe cases of these rare conditions, unresponsive to conventional treatment (*strength of recommendation IIa*; Table [10](#Tab10){ref-type="table"}). Table 10The use of intravenous immunoglobulins in oncological diseasesResults/responseNumber of patientsIntervention including dose and IVIg preparation usedStudy designRef.DiseaseConsiderable improvement of KS skin lesions after 2 weeks, disappearance of 6 of 8 skin lesions after 1 month; after 3 cycles, only 1 remnant skin lesion; after 2 years of monthly treatment, no relapse of KS or progression of polymyositis45-year-old patient with polymyositis, who developed KS when given immunosuppressive therapy for polymyositisIVIg 0.4 g/kg per day for 5 days (Sandoglobulin®, Sandoz, Switzerland) adjunctive to low-dose PDCase report\[[@CR326]\]Kaposi\'s sarcoma (KS)2 of 9 (22%) patients had stabilization of disease (one for 8 months)9 patients with metastatic melanomaIVIg 1 g/kg (VIGAM® LIQUID, BPL, UK, contains 0.5 g sucrose per gram of immunoglobulin) given over a 1- to 3-day period at a maximum dose of 25 g/day for up to 8 h, every 3 weeks (during 3 or 6 months in case of nonprogression according to CT/MRI) adjunctive to standard therapyUncontrolled trial\[[@CR327]\]Metastatic melanomaNo mucositis after MTX treatment followed by IVIg in both cases15-year-old male and a 5-year-old girl, who developed grade 3 mucositis after every course of MTX0.2 g IVIg/kg applied 27 h after the 24-h MTX infusionCase report\[[@CR328]\]Chemotherapy-induced oral mucositisComplete remission of thymoma after 4 cycles of IVIg confirmed by FDG-PETA patient with metastatic malignant thymoma and myasthenic crisisIVIgCase report\[[@CR329]\]Thymus carcinomaCase 1 developed immunodeficiency 2 years after the resection of thymoma, maintained with IVIg and low-dose CS; case 2 was maintained with IVIg and was stable but developed Kaposi sarcoma 3 years afterwardsCase 1---a 51-year-old womanMonthly IVIg 0.4 g/kgCase report\[[@CR330]\]Thymoma and immunodeficiency (Good syndrome)Case 2---an 89-year-old man

Kaposi\'s sarcoma {#Sec99}
-----------------

### Level of evidence C {#d29e9176}

A patient with polymyositis and Kaposi sarcoma had remission of both conditions on IVIg therapy (*strength of recommendation IIb*).

Metastatic melanoma {#Sec100}
-------------------

### Level of evidence C {#d29e9187}

Stabilization of metastatic melanoma was shown in the small group of patients after addition of IVIg to standard therapy (*strength of recommendation IIb*).

Chemotherapy-induced oral mucositis {#Sec101}
-----------------------------------

### Level of evidence C {#d29e9198}

IVIg was shown to be effective in preventing severe recurrent chemotherapy-induced oral mucositis in two patients treated with methotrexate (*strength of recommendation IIa*).

Thymus carcinoma {#Sec102}
----------------

### Level of evidence C {#d29e9209}

Anecdotal case report describes complete remission of metastatic malignant thymoma after four cycles of IVIg given to myasthenic patient (*strength of recommendation IIb*).

Thymoma and immunodeficiency (Good syndrome) {#Sec103}
--------------------------------------------

### Level of evidence C {#d29e9221}

After thymectomy, two patients with Good syndrome were maintained with IVIg for developed immunodeficiency; one of them developed Kaposi sarcoma after 3 years (*strength of recommendation IIb*; Table [11](#Tab11){ref-type="table"}). Table 11The use of intravenous immunoglobulins in endocrine disordersResults/responseNumber of patientsIntervention including dose and IVIg preparation usedStudy designRefDisease21 of 26 patients showed improvement of the mean Neuropathy Impairment Score (NIS) from 61.5 ± 26.0 to 33 ± 29.6 (*p* \< 0.001); improvement of NIS was more frequent in patients with a conduction block (100%) vs. in those who did not (66.7%; *p* = 0.03); relapses occurred less in the responders who had a conduction block (9.1%) vs. in those who did not (50%; *p* = 0.04)26 patients with DDP evaluated at baseline, at the end of 4 weeks of IVIg therapy, afterwards every few months, mean follow-up period of 25 months.IVIg 0.4 g/kg for 5 daysProspective open label\[[@CR331]\]Diabetic demyelinating polyneuropathyReached 80% reduction of pains and significant recovery of muscle strengthA 57-year-old man with type 2 diabetes and painful proximal diabetic neuropathy with muscle weakness and atrophyIVIg 0.4 g/kg for 5 daysCase report\[[@CR332]\]Proximal diabetic neuropathyAll defective cranial nerve findings disappeared during the 1st month and did not recur during 8 months of follow-upA 55-year-old woman, with 12-year history of DM, developed simultaneous right VII and left III, IV, and VI cranial nerve pulsesIVIg 0.4 g/kg for 5 daysCase report\[[@CR333]\]Cranial nerve neuropathy in diabetes mellitus5 days after IVIg easy fatigability of thigh disappeared and of the strength of shoulder girdle muscle improved; 1 year after IVIg treatment, there was normal muscle strength and significant improvement of atrophyA 45-year-old man with IDDM and diabetic amyotrophyIVIg 0.4 g/kg per day for 5 daysCase report\[[@CR334]\]Diabetic amyotrophyRapid improvement of fasting serum glucose levels, stabilization of renal function, and decrease in the donor-specific class II antibodiesA 44-year-old man with long-standing poorly controlled IDDM3 doses of 0.5 g/kg per day of IVIg, started on day 14 posttransplant and given every other day adjunctive to standard posttransplant therapy, plasmapheresis, and rituximabCase report\[[@CR335]\]Pancreas allograft rejectionPartial response to IVIg and complete resolution of weakness after CP, asymptomatic after 1 year without treatmentA 17-year-old man with known IDDM and a subclinical Hashimoto\'s thyroiditis and a new onset of asymmetric weakness and atrophy in armsMonthly infusions of IVIg 0.4 g/kg per day for 5 consecutive days followed by 6 cycles of CP 1 g/m^2^Case report\[[@CR336]\]Multifocal motor neuropathy, type 1 diabetes, and Hashimoto\'s thyroiditisWithin 10 weeks after IVIg, muscle weakness and sensory disturbances disappeared, but tendon reflexes stayed slightly depressed; the patient was treated with IVIg every 3 months due to IVIg-dependent courseA 64-year-old man with clinical and laboratory findings supportive for MMN, high titers of anti-GM1-Abs and subclinical Hashimoto\'s thyroiditisIVIg 0.4 g/kg per day for 5 days, repeated every 3 months due to IVIg-dependent course of the diseaseCase report\[[@CR337]\]Multifocal motor neuropathy and Hashimoto\'s thyroiditisPartial response to CS and IVIg and antiepileptic medication (probably due to lowering of seizure threshold by antithyroid drugs and beta-blockers); continued with immunosuppressive therapy (high-dose CS and AZA) but relapsed after 2 months, recovered after thyroidectomyA 34-year-old woman with encephalopathy and thyrotoxic Hashimoto\'s thyroiditisIVIg 2 g/kg in 3 days adjunctive to high-dose CS and plasmapheresisCase report\[[@CR338]\]Thyrotoxic autoimmune encephalopathySee ophthalmology sectionGrave\'s ophthalmopathyAll had normalization of VLCFA within 3 months, but neurological status continued to deteriorate in both groups6 of 12 patients with X-linked childhood and adolescent adrenoleukodystrophy received IVIg in addition to diet and GTOE supplementIVIg 1 g/kg in 8--12 h (Gamma globulin; Merieux, France) every 15 days for 3 months and every month for a year, thereafter; both groups received very-long-chain fatty acids (VLCFA)-restricted diet and supplement of 40 mg/day glycerol trioleate and erucic acids (GTOE)RCT\[[@CR339]\]Adrenoleukodystrophy3/9 improved; 3/9 remained stable; 3/9 deteriorated and died9 adult patients with various X-ALD phenotypes15 cycles of 1 g/kg 7 S-immunoglobulin (Venimmun, Behring, Germany)Uncontrolled trial\[[@CR340]\]Recovery of adrenal function but dependence on dialysis 18 months laterA 20-year-old man with Waterhouse--Friderichsen syndrome and bilateral renal cortical necrosis secondary to meningococcal sepsisNeither protocol nor IVIg preparation is available; IVIg adjunctive to aggressive treatment with antibiotics, CS, vasopressors, plasmapheresis, and dialysisCase report\[[@CR341]\]Waterhouse--Friderichsen syndromeDuring IVIg treatment, normalization of thyroid function, some nonovulatory menses, and reduction of antibody titers were observedA female with autoimmune polyendocrine syndrome type 2IVIgCase report\[[@CR342]\]Autoimmune polyendocrine syndrome

### Summary {#d29e9551}

There are still no randomized controlled trials evaluating efficacy of IVIg and it cannot be recommended for treatment of epithelial or other solid malignancies.

Diabetes mellitus {#Sec104}
-----------------

### Level of evidence C {#d29e9559}

There is some evidence that IVIg therapy can improve the Neuropathy Impairment Score in patients with diabetic demyelinating polyneuropathy (*strength of recommendation IIa*). A few case reports describe regression of symptoms of proximal diabetic neuropathy, diabetic amyotrophy, and cranial nerve neuropathy in different diabetic patients treated with IVIg (*strength of recommendation IIa*). We conclude that evidence for the use of IVIg in diabetic neuropathies is poor and its systematic use cannot be recommended.

Hashimoto\'s encephalopathy {#Sec105}
---------------------------

### Level of evidence C {#d29e9573}

A rare case of autoimmune encephalopathy during thyrotoxic phase of Hashimoto\'s disease only partially responded to immunosuppressive therapy with adjuvant intravenous immunoglobulin (*strength of recommendation IIb*).

X-linked adrenoleukodystrophy {#Sec106}
-----------------------------

### Level of evidence B {#d29e9584}

Therapeutic efforts including dietary therapy and immunomodulation with IVIg fail to improve prognosis in patients with X-linked adrenoleukodystrophy and BMT remains the only treatment that can reverse early neurological manifestations and adrenal impairment of ALD (*strength of recommendation III*).

Waterhouse--Friderichsen syndrome {#Sec107}
---------------------------------

### Level of evidence C {#d29e9595}

No evidence supports the use of IVIg in Waterhouse--Friderichsen syndrome due to meningococcal sepsis (*strength of recommendation III*).

Autoimmune polyendocrine syndrome {#Sec108}
---------------------------------

### Level of evidence C {#d29e9606}

No evidence supports the use of IVIg in autoimmune polyendocrine syndrome type 2 (*strength of recommendation IIb*; Table [12](#Tab12){ref-type="table"}). Table 12The use of intravenous immunoglobulins in neurological diseasesDiseaseRef.Study designIntervention including dose and IVIg preparation usedNumber of patientsResults/responseOpsoclonus myoclonus\[[@CR343]\]Case reportsIVIg 3 doses of 0.3 g/kg over 4 months + rituximab2 patients with postinfectious opsoclonus myoclonus syndromeSignificant clinical improvement without relapses\[[@CR344]\]Case reportIVIg 0.4 g/kg per day for 5 days + prednisolone + clonazepamA 41-year-old woman with idiopathic opsoclonus myoclonus syndromeComplete recovery\[[@CR345]\]Case reportIVIg 30 g/day for 5 days with 5 repeated doses after 2 months + CSA 36 year-old man with parainfectious opsoclonus myoclonus syndromeAccelerated recovery\[[@CR346]\]Case reportIVIg + ACTH + CSA patient with childhood-onset opsoclonus myoclonusPartial recovery\[[@CR347]\]Case reportIVIg initially 5.5 g and 6 additional courses at a dosage of 2.5 g and 7 courses at a dosage of 5 g every 2 to 3 weeks + ACTHA 22-month-old girl with neuroblastoma-associated opsoclonus myoclonusPartial recovery\[[@CR348]\]Case reportIVIg + ACTHA 27-year-old woman with severe opsoclonus myoclonusComplete recovery\[[@CR349]\]Case reportIVIg 1 g/kg for 2 days with 12 additional doses given every 4--6 weeksAn 18-month-old black girl with neuroblastoma-associated opsoclonus myoclonusComplete recovery\[[@CR350]\]Case reportHigh-dose IVIgA 14-month-old male with infantile opsoclonus myoclonusComplete recovery\[[@CR351]\]Retrospective studyIVIg + CS9 patients with idiopathic and paraneoplastic opsoclonus myoclonusIdiopathic opsoclonus myoclonus: 2/9 complete recovery, 1/9 partial recovery, 2/9 remissionParaneoplastic opsoclonus myoclonus: 3/9 no response, 1/9 partial recoveryPANDAS\[[@CR352]\]RCTIVIg I g/kg per day for 2 days vs PP vs placebo29 children with severe infection-triggered exacerbations of obsessive-compulsive disorder (OCD) or tic disorders, including Tourette syndromeAt 1 month, significant improvement in global impairment (*p* = 0.0009), obsessive- compulsive symptoms (*p* = 0.006), anxiety (*p* = 0.001), depression (0.002); at 1 year, more than 80% of patients receiving IVIg or PP remained improvedMultiple sclerosis (MS)\[[@CR353]\]RCTIVIg 0.2 g/kg--0.4 mg/kg every 4 weeks for 48 weeks vs placebo127 patients with relapsing--remitting multiple sclerosis (RRMS)At 1 year, there was no significant difference in the proportion of relapse-free patients among treated groups\[[@CR354]\]RCT (primary and secondary chronic progressive MS)IVIg 0.4 g/kg per month for 24 months vs placebo231 patients with primary (PPMS) and secondary (SPMS) chronic progressive MSIVIg can delay progression of disease in primary chronic progressive MS; no significant difference in progression was noted for secondary chronic progressive MS; no improvement in neurological functions with IVIg\[[@CR355]\]RCT (secondary progressive MS)Monthly IVIg 1 g/kg for 27 months vs placebo34 patients with secondary progressive (SP) MSNo reduction in the relapse rate or the progression of disability\[[@CR356]\]Retrospective study (relapsing--remitting MS)IVIg treatment at a mean time of 3.4 ± 1.8 years at a mean dose of 15.5 ± 8.3 g/month308 patients with RRMS69% reduction of mean annual relapse rate was observed after IVIg treatment initiation\[[@CR357]\]RCT (secondary progressive MS)IVIg 1 g/kg per month for 27 months vs placebo318 patients with secondary progressive multiple sclerosisNo effect on the time to confirmed progression on the EDSS, annual relapse rate, and the change in T2 lesion load on MRI\[[@CR358]\]Meta-analysisIVIg 0.15--2 g/kg for 12--24 months vs placebo4 RCT (265 patients with RRMS)Significant beneficial effect: on the annual relapse rate (*p* = 0.00003), on the proportion of relapse-free patients (*p* = 2.1 × 10^−8^)\[[@CR359]\]RCTIVIg 0.15--0.2 g/kg per month for 2 years vs placebo148 patients with RRMSProgression of disability was reduced in 24% of the patients with therapeutic efficacy to be noted in the first 6 months of the treatment\[[@CR360]\]RCT (relapsing remitting MS)IVIg 0.4 g/kg for 5 days followed by once every 2 months for 2 years vs placebo40 patients with RRMSReduction in yearly exacerbation rate (*p* = 0.0006 (overall))\[[@CR361]\]RCT (relapsing remitting MS)IVIg 1 g/kg for 2 days every 4 weeks for 24 weeks vs placebo17 patients with relapsing--remitting or relapsing progressive multiple sclerosis11 had no exacerbations during IVIg treatment compared with only 6 on placebo (*p* = 0.05)Guillain--Barré syndrome (GBS)\[[@CR362]\]Systematic review meta-analysisIVIg 0.2--1 g/kg per day for 2--6 days vs PP vs immunoabsorption vs supportive care11 RCT (913 patients)Improvement on the disability grade scale with intravenous immunoglobulin (IVIg), weighted mean difference WMD of 0.02 (95% confidence interval (CI) 0.25 to 0.2); no significant difference between IVIg and plasma exchange\[[@CR363]\]Open-labeled studyIVIg 0.4 g/kg per day for 5 days11 patients younger than 15 years old, diagnosed with moderate or severe GBSAfter 2 weeks, 72.7% of patients improved by one or more grades and 36.4% improved by 2 or more grades, measured on the Hughes\' functional grade FG scaleAfter 4 weeks, 81.8% of patients improved by one or more grades and 63.6% of patients improved by 2 or more grades\[[@CR364]\]RCTIVIg 0.4 g/kg per day for 3 or 6 days39 patients with Guillain--Barré syndromeNo significant difference in time to assisted walking in the 2 groups (*p* = 0.08); significantly shorter time to assisted walking in ventilated patients in the 6-day group (*p* = 0.04)\[[@CR365]\]RCT (IgG anti-GM1-positive subgroup)IVIg vs plasmapheresis24 patients with Guillain--Barré syndromeIVIg-treated patients had: significantly lower Hughes grade scores 1, 3, and 6 months after onset (*p* = 0.03); higher probability to regain independent locomotion at 6 months (*p* = 0.044); more frequent rapid recovery within 4 weeks (*p* = 0.03)Plasma exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group\[[@CR366]\]RCTIVIg 0.4 g/kg per day for 5 days vs plasma exchange379 adult patients with Guillain--Barré syndromeIVIg is equivalent to plasmapheresis in reducing the amount of disability at 4 weeks after treatment\[[@CR367]\]RCTIVIg 0.4 g/kg per day for 5 days vs plasma exchange150 patients with Guillain--Barré syndrome53% of patients treated with IVIg improved compared to 34% in the PP group (*p* = 0.024)Paraproteinemic neuropathy (IgM)\[[@CR368]\]Systematic reviewIVIg or interferon alpha or plasma exchange5 trials (97 patients with IgM antimyelin-associated glycoprotein paraproteinemic neuropathy)2 trials with 33 patients suggest that IVIg may sometimes produce short-term benefit (in terms of improvement in Modified Rankin Scale at 2 weeks and 10-m walk time at 4 weeks) and is relatively safe\[[@CR369]\]Crossover RCTIVIg 2 g/kg over 1 to 2 days vs placebo22 patients with paraproteinemic demyelinating neuropathyAfter 4 weeks, the overall disability significantly decreased during the IVIg period (*p* = 0.001) compared to the placebo period where it was unchanged; the mean difference between the treatment effects was significant (*p* = 0.05)\[[@CR370]\]Crossover RCTIVIg vs placebo given monthly for 3 months11 patients with demyelinating polyneuropathy associated with monoclonal IgM antibodiesModest benefit with IVIgAmyotrophic lateral sclerosis\[[@CR371]\]Case seriesIVIg 0.4 g/kg per day for 5 days followed by monthly 2-day infusions + CP7 patients with amyotrophic lateral sclerosisAll patients worsened according to MRC and/or bulbar and/or Rankin scores\[[@CR372]\]Case seriesIVIg monthly for 3 months9 patients with rapidly progressive amyotrophic lateral sclerosisAll patients worsened after 3 months with decrease in mean total muscle scores (megascores)Lambert--Eaton myasthenic syndrome\[[@CR373]\]Crossover RCTIVIg 1 g/kg per day for 2 days vs placebo9 with Lambert--Eaton myasthenic syndromeIVIg showed significant improvements in limb, respiratory, and bulbar muscle strength measures (*p* = 0.017 to 0.038) and a significant decline in serum calcium channel antibody titers (*p* = 0.028)Stiff person syndrome\[[@CR374]\]Case seriesIVIg3 patients with active disease and/or disease refractory to treatment with diazepam and/or CSImprovement after treatment\[[@CR375]\]Uncontrolled pilot studyIVIg3 patients with stiff-man syndromeImprovement after treatment\[[@CR376]\]Case reportIVIgA patient with refractory stiff-man syndromeLong-term remission after treatment\[[@CR377]\]Crossover RCTIVIg 2 g/kg once a month for 3 months vs placebo14 patients with stiff-person syndrome and anti-GAD65 antibodiesAccording to stiffness scores, IVIg was superior compared to placebo in direct treatment effect (*p* = 0.01) and in first-order carryover effect (*p* = 0.001)Adrenoleukodystrophy\[[@CR378]\]RCTIVIg 1 g/kg per day every 15 days for 3 months and every month for 1 year + VLCFA-restricted diet + GTOE vs VLCFA-restricted diet + GTOE12 X-linked adrenoleukodystrophyNo significant differences in deterioration of neurological symptoms in the 2 groups according to EDSS scoreIntractable childhood epilepsy\[[@CR379]\]RCTIVIg 0.1--0.4 g/kg (7 infusions in 6 weeks total time) vs placebo61 patients with refractory epilepsy (46 with partial epilepsy)No significant difference between the groups studied; no relationship between IVIg dose and efficacy\[[@CR380]\]Crossover RCTIVIg 0.4 g/kg (Sandoglobulin) 2 infusions each with an interval of 2 weeks vs placebo10 patients aged 4--14 years with Lennox--Gastaut syndrome2/10: immediate reduction in their high-frequency and invariable seizure activity from 42% to 100% and a less abnormal EEG8/10: unchanged general condition, no EEG changesCritical illness polyneuropathy\[[@CR381]\]Retrospective chart analysisIVIg 0.3 g/kg per day for 3 days16 patients with critical illness polyneuropathy following multiple-organ failure and gram-negative sepsis8/16 patients of MOF with sepsis without the development of CIP had been treated with IVIg immediately after the diagnosis of sepsis7/16 who eventually developed CID were not treated with IVIg\[[@CR382]\]Case seriesIVIg3 patients with critical illness polyneuropathyNo improvement after treatmentRasmussen\'s encephalitis\[[@CR383]\]Case seriesIVIg, CS, CP, therapeutic PP (TPE), protein A, immunoglobulin G (IgG), immunoadsorption (PAI)15 patients with Rasmussen encephalitis (14 with childhood and one with adolescent onset)In 11 patients treated with IVIg, 1 had reduction of seizure frequency by \>50% and improvement of neurologic condition or resolution of status epilepticus and 2 had reduction of seizure frequency by up to 50%; in the rest, 5 had no effect and in the 3 effect was not assessable\[[@CR384]\]Case reportIVIg 0.4 g/kg per day for 5 days once a monthA 45-year-old woman with adult-onset Rasmussen encephalitisImprovement after IVIg therapy with a \>75% reduction in seizures and mild improvement in neurologic performances\[[@CR385]\]Case reportsIVIg 0.4 g/kg per day for 5 days once a month2 patients with advanced adult-onset Rasmussen\'s encephalitisSignificant improvement in seizure control, hemiparesis, and cognition\[[@CR386]\]Case seriesIVIg ± high-dose CS19 patients with Rasmussen\'s encephalitis8/9 patients receiving IVIg had some reduction of seizure frequency and mild improvement in hemiparesisChronic inflammatory demyelinating polyradiculoneuropathy\[[@CR387]\]Crossover RCTIVIg 1 to 2 g/kg over 1 to 2 days every 3 weeks for 24 weeks vs placebo117 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)54% of patients treated with IVIg and 21% treated with placebo improved according to INCAT disability score (*p* = 0.0002); IVIg patients had a longer relapse time compared with placebo (*p* = 0.011) in the extension phase\[[@CR388]\]Crossover RCTIVIg 2 g/kg over 1 to 2 days vs oral prednisolone for 6 weeks24 patients with CIDPBoth treatments showed marked improvement in INCAT disability scores after 2 weeks; no significant difference between the 2 treatments\[[@CR389]\]RCTIVIg 1 g/kg per day for 2 days vs placebo53 patients with untreated CIDPAverage muscle score (AMS) was significantly improved in the IVIg group (*p* = 0.0006) at day 42; IVIg significantly improved nerve conduction; according to Hughes' functional disability scale IVIg group showed better improvement than placebo (*p* = 0.019)\[[@CR390]\]Crossover RCTIVIg 0.4 g/kg per day for 5 days vs placebo30 patients with definite or probable CIDP of chronic progressive (16 patients) or relapsing (14 patients) courseAt 4 weeks, significant improvement with IVIg in neurological disability score (NDS; *P \< *0.0001) in clinical grade (CG; *P \< *0.002) and in grip strength (GS; *P \< *0.001); significant improvement in summed MCV (*P \< *0.0001) and in summed (CMAP) amplitudes (*P \< *0.03)Myasthenia gravis\[[@CR391]\]Systematic reviewIVIg vs no treatment or placebo or plasma exchange6 RCT (*n* = 371)There is insufficient evidence to determine the efficacy of IVIg in myasthenia gravis\[[@CR392]\]RCTIVIg 2 g/kg over 2 days vs placebo51 patients with worsening weakness due to myasthenia gravisAccording to quantitative myasthenia gravis (QMG) score at day 14, there was a significant improvement in the IVIg group (*p* = 0.047) which continued at day 28\[[@CR393]\]RCTIVIg 2 g/kg vs placebo15 patients with myasthenia gravisNo significant differences between the 2 groups were noted at day 42 according to QMG score\[[@CR394]\]Crossover RCTIVIg 0.4 g/kg for 5 days vs plasma exchange12 patients with generalized moderate to severe myasthenia gravis on immunosuppressive treatment for at least 12 monthsAfter 1 and 4 weeks of treatment, a significant improvement was noted according to QMG score in both groups; no significant difference between them\[[@CR395]\]Case seriesIVIg 0.04 g/kg per day for 5 days and maintenance every 6 weeks10 patients with severe generalized myasthenia and an acute deterioration unresponsive to conventional therapySignificant improvement according to Osserman scale at 1 year (*P* \< 0.001) in all patientsAcute disseminated encephalomyelitis\[[@CR396]\]Case reportIVIg 2 g/kg once and repeat bolus of 150 g on week 3 and 4; previews treated with CS with no responseA 20-year-old male with postvaccination acute disseminated encephalomyelitisRapid response with partial recovery over 1 year\[[@CR397]\]Case seriesIVIg 2 g/kg over 2 days or MP or IVIg 2 g/kg over 2 days + MP16 children with severe acute disseminated encephalomyelitis1 patient treated with IVIg and 10 patients treated with CS alone had complete response; from 5 patients treated with combined therapy, 2 had complete response and 3 partial or no response\[[@CR398]\]Case seriesIVIg 0.4 g/kg per day for 5 days5 adult patients, 3 of them affected by classic disseminated encephalomyelitis and 2 by a postinfectious myelitisMarked functional improvement in all patients starting from day 5 with maximum effect at 3 weeks\[[@CR399]\]Case reportIVIg + CS for 3 daysA child with atypical acute disseminated encephalomyelitisComplete response\[[@CR400]\]Case reportIVIg + CSA 3-year-old boy with severe acute disseminated encephalomyelitisComplete response\[[@CR401]\]Case reportsIVIg 30 g/day for 5 days and 3 additional monthly courses of 30 g + CS2 adult women with acute disseminated encephalomyelitisComplete response in both patientsIVIg 50 g/d for 2 days + CS.Autism\[[@CR402]\]Case seriesIVIg 0.04 g/kg monthly for 6 months7 patients with childhood autismNo statistically significant changes on behavioral measures after 6 months*PANDAS* pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

Acute disseminated encephalomyelitis {#Sec109}
------------------------------------

### Level of evidence C {#d29e10975}

There is weak evidence coming out from several case reports that IVIg may be a useful treatment option either as a combination therapy with CS or in cases that steroid treatment fails (*strength of recommendation I*).

Adrenoleukodystrophy {#Sec110}
--------------------

### Level of evidence B {#d29e10986}

Taking into consideration the limited evidence (one RCT) and the unfavorable effect of IVIg treatment, at this point, IVIg should not be used as treatment of adrenoleukodystrophy (*strength of recommendation III*).

Amyotrophic lateral sclerosis {#Sec111}
-----------------------------

### Level of evidence C {#d29e10997}

No benefit was observed from the use of IVIg in two case series. Considering the weak evidence and the negative outcome, IVIg is not recommended for the treatment of amyotrophic lateral sclerosis (*strength of recommendation III*).

Autism {#Sec112}
------

### Level of evidence C {#d29e11008}

The use of IVIg in autism is only limited to case series and the effect is questionable. IVIg is not recommended at the moment for the treatment of autism (*strength of recommendation III*).

Chronic inflammatory demyelinating polyneuropathy {#Sec113}
-------------------------------------------------

### Level of evidence A {#d29e11019}

Several RCTs evaluated the effectiveness of IVIg. The results of these studies are strongly pointing to the useful effect of IVIg in patients with chronic inflammatory demyelinating polyneuropathy. IVIg should be considered as an additional option in combination with other immunosuppressive agents (*strength of recommendation I*).

Opsoclonus myoclonus {#Sec114}
--------------------

### Level of evidence C {#d29e11031}

In this rare syndrome, IVIg was reported in several case reports and a retrospective study proved that it induced significant response. Although there is no strong evidence, IVIg may be considered as an additional option in treatment of opsoclonus myoclonus (*strength of recommendation I*).

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections PANDAS {#Sec115}
-----------------------------------------------------------------------------------------------

### Level of evidence B {#d29e11042}

Results coming from one small RCT testing the effect of IVIg showed significant improvement in symptoms; therefore, IVIg is recommended as an additional option for treatment of PANDAS (*strength of recommendation I*).

Multiple sclerosis {#Sec116}
------------------

### Level of evidence A {#d29e11053}

Data from several RCTs and a meta-analysis showed significant differences between IVIg and placebo favoring the use of IVIg in relapsing--remitting multiple sclerosis (MS). On the other hand, a recent RCT including 127 with relapsing--remitting MS treated with IVIg or placebo showed no significant difference in the proportion of relapse-free patients among treated groups. Another recent RCT including 231 patients showed that IVIg can delay progression of disease in primary chronic progressive MS but no significant difference in progression was noted for secondary chronic progressive MS. To conclude, IVIg may be used as an alternative therapy in relapsing--remitting MS and in primary chronic progressive MS when standard immunosuppression therapy fails (*strength of recommendation IIb*).

Guillain--Barré {#Sec117}
---------------

### Level of evidence A {#d29e11064}

There is strong evidence, several randomized controlled trials, and a meta-analysis that prove that IVIg is of benefit in improving the disability grade in patients with Guillain--Barré syndrome. No significant difference between IVIg and PP was found. IVIg should be considered as a treatment option in Guillain--Barré syndrome (*strength of recommendation I*).

Paraproteinemic neuropathy (IgM) {#Sec118}
--------------------------------

### Level of evidence A {#d29e11075}

There is no reliable evidence to recommend the use of IVIg in paraproteinemic neuropathy. A restricted number of RCT and a systematic review showed only modest benefit with IVIg in the short term (*strength of recommendation IIb*).

Lambert--Eaton myasthenic syndrome {#Sec119}
----------------------------------

### Level of evidence B {#d29e11086}

A single small RCT showed significant improvement in patients suffering from Lambert--Eaton myasthenic syndrome with the use of IVIg compared to placebo. Therefore, it is acceptable to consider the use of IVIg in this rare and severe neurological syndrome (*strength of recommendation I*).

Stiff-person syndrome {#Sec120}
---------------------

### Level of evidence B {#d29e11097}

Data from a small randomize control trial and several case reports showed that the use of IVIg led to significant improvement in patients with stiff-person syndrome and was superior to placebo. IVIg should be considered as a treatment option in this syndrome especially if the first-line treatment fails (*strength of recommendation I*).

Intractable childhood epilepsy {#Sec121}
------------------------------

### Level of evidence A {#d29e11108}

Two RCTs investigated the efficacy of IVIg in patients with intractable childhood epilepsy compared with placebo. Results from these studies do not support benefit from the use of IVIg. Therefore, IVIg is not recommended for the treatment of intractable childhood epilepsy (*strength of recommendation III*).

Critical illness polyneuropathy {#Sec122}
-------------------------------

### Level of evidence C {#d29e11119}

There is no reliable evidence (level of evidence C-III) to recommend the use of IVIg in the treatment of critical illness polyneuropathy (*strength of recommendation III*).

Rasmussen\'s encephalitis {#Sec123}
-------------------------

### Level of evidence C {#d29e11130}

There is weak evidence indicating significant benefit of IVIg in Rasmussen's encephalitis either used as monotherapy or combined with other therapies. It should be considered as one of the treatment options in this disease (*strength of recommendation I*).

Myasthenia gravis {#Sec124}
-----------------

### Level of evidence A {#d29e11141}

Several RCTs and a meta-analysis examined the efficacy of IVIg in patient with myasthenia gravis. Results are conflicting. A recent meta-analysis concluded that there is insufficient evidence to determine the efficacy of IVIg in myasthenia gravis. IVIg may be used as treatment for myasthenia gravis severe acute exacerbations (*strength of recommendation IIa*; Table [13](#Tab13){ref-type="table"}). Table 13The use of intravenous immunoglobulins in immunodeficienciesDiseaseRef.Study designIntervention including dose and IVIg preparation usedNumber of patientsResults/responseX-linked agammaglobulinemia (XLA)\[[@CR403]\]Retrospective trialIVIg was given at doses of \>0.25 g/kg every 3 weeks (mean individual residual IgG levels of 700 mg/dl); 24 patients received IVIg from the "Establissements de Transfusion Francais," others Sandoglobulin (Novartis Institute, Basel) and Endoglobulin (Immuno France, Marseilles) for 3,690 cumulated months31 patients with XLA at mean age of 24 months followed for a median time of 123 monthsThe incidence of bacterial infections requiring hospitalization fell from 0.4 to 0.06 per patient year (*p* \< 0.001); the incidence of bacterial infections requiring hospitalization was lower for the periods when patients had residual level of IgG \> 800 mg/dl than for the period of levels \< 800 mg/dl (*p* \< 0.001); however, viral or unidentified infections still developed (enteroviral meningitis 3, exudative enteropathy 3, aseptic arthritis 1); at last follow-up, 30 patients were alive at median age of 144 months (range, 58 to 253)\[[@CR404]\]Retrospective trialPatients were treated with different regiments of IVIg between 1965 and 1990; 20 patients were treated before any IVIg was available, 14 patients received IMIg in dose of \<0.1 g/kg every 3 weeks; 9 patients were treated at dosages up to 0.2 g/kg every 3 weeks; 15 patients received IVIg at dosages between 0.35 and 0.6 g/kg every 3 weeks (patients receiving different replacement regiments were assigned to more than one group if they received respective regiment for a minimum of 1 year)29 patients with XLAA significant increase in trough serum IgG (*p* = 0.0001) and a significant decrease in the incidence of pneumonias (*p* = 0.038) and number of days spent in the hospital in high-dose IVIg group compared with other groups (*p* = 0.005); improvement in therapeutic outcome was particularly evident when high-dose IVIg was started before the age of 5; bacterial meningitis, chronic pulmonary disease, and bronchiectasis occurred in IMIg but not in any of IVIg groups\[[@CR405]\]Retrospective trialIVIg 0.3--0.4 g/kg every 3 to 4 weeks23 patients with XLA treated with IVIg for a mean period of 6.8 ± 4.1 yearsSignificant decrease of the incidence of pneumonia requiring treatment or hospitalization (*p* = 0.006) and hospitalizations due to pneumonia (*p* = 0.08)\[[@CR406]\]RCTGamaSTAN 20 ml in 2 IM injections every 4 weeks vs. 0.15 g/kg IVIg every 4 weeks (Cutter Laboratories, Inc., Berkeley, CA, USA) during 242 months of treatment22 patients with antibody deficiency (9 with XLA); 14 (5 with XLA) received IVIg, 13 (7 with XLA) received ISg; 7 patients (3 with XLA) received both ISg and IVIg in separate coursesLess acute infections per month of treatment in IVIg group (*p* \< 0.01; in XLA subgroup, mean 0.8 vs. 2.7); in patients who received separate courses of both IVIg and SIg, infection rate was lower on IVIg (*p* \< 0.05; in XLA subgroup, mean 0.3 vs. 4.7)\[[@CR407]\]RDB crossoverStandard-dose IVIg (adults 300 mg/kg and children 0.4 g/kg every 4 weeks) for 9 months, followed by 3-month washout period and high-dose IVIg (adults 0.6 g/kg and children 0.8 g/kg every 4 weeks) or vice versa (Immunoglobuline IV, Sanquin Blood Supply Foundation, the Netherlands)41 patients with primary hypogammaglobulinemia (19 patients with XLA)High-dose therapy significantly reduced the number (mean, 3.5 vs. 2.5 per patient (*p* = 0.004) and 4.3 vs. 3.4 in XLA subgroup) and duration (median, 33 vs. 21 days (*p* = 0.015), in XLA subgroup 28.5 vs. 19 days) of infectionsWiscott--Aldrich syndrome (WAS)\[[@CR408]\]Retrospective trialIVIg 0.18--0.58 g/kg every 2--4 weeks and antibiotic prophylaxis with acyclovir and/or fluconazole in some cases21 patients with WASOnly 4 episodes of sever acute bacterial infection in 451 patient months after splenectomyHyper-IgE syndrome (Job syndrome)\[[@CR409]\]Case seriesIVIg3 adult patients with hyper-IgE syndromeMarked improvement in tendency to infections\[[@CR410]\]Case reportMonthly IVIg and interferon gamma three times a week since age 3; he received also prophylaxis with antibiotic and fluconazole15-year-old boy with hyper-IgE syndromeGood control of disease\[[@CR411]\]Case reportIVIg 2 g/kg (Venoglobulin I-Alpha Therapeutic Corporation, Los Angeles, CA, USA) monthly for 7 coursesPatient with hyper-IgE syndromeNo improvement\[[@CR412]\]Case seriesIVIg8 children with recurrent infections, failure to thrive, hypergammaglobulinemia and IgG2 subclass deficiencyClinical resolution\[[@CR413]\]Case seriesIVIg (Sandoglobulin) 6--12 g monthly3 members of a family (2 children, 1 adult) with recurrent severe respiratory infections and IgG2 subclass deficiencyClinical resolutionIgG subclass deficiencies\[[@CR414]\]Case reportIVIg monthly 7 coursesA-6-year old child with chronic rhinosinusitis, nasal polyps and IgG3 deficiencyClinical improvement\[[@CR415]\]Case reportIVIg monthlyA 2-year-old child with recurrent sinopulmonary infections and IgG2 deficiencyClinical improvement\[[@CR416]\]Cases reportIVIg 10--15 g every 3 weeks for 6 months2 patients with treatment-resistant osteomyelitis of the jaw, one with IgG2 deficiency, and the other with IgG3 deficiencyClinical improvement in both patientsSpecific antibody deficiency\[[@CR417]\]Retrospective studyPart of this patients received IVIg75 patients with recurrent infections and low response to pneumococcal polyvalent vaccineReduction in number of infections\[[@CR202]\]Series reportIVIg9 children with recurrent sinopulmonary infections and poor response to *Haemophilus influenzae* type b capsular polysaccharideReduction of infections upon start of IVIg treatment and recurrence after discontinuation\[[@CR418]\]Case reportIVIgPatient with Smith--Lemli--Opitz syndrome, frequent infections and absent response to PneumovaxSame frequency of infections, less severityHyper-IgM syndrome (HIGM)\[[@CR419]\]Case control studyIVIg was administered every 4 weeks and serum IgG levels were consistently maintained above 4 or 5 g/l in most patients29 patients with HIGM due to activation-induced cytidine deaminase deficiency, suffering from recurrent infectionsAfter IVIg therapy was initiated, frequency of infections markedly decreased\[[@CR420]\]Case controlIVIg9 patients with HIGM and recurrent infectionsRegression in the manifestations of infection\[[@CR421]\]Case controlIVIg, 0.25--0.3 g/kg every 4 weeks for 1 year6 patients with HIGM and recurrent infectionsSeverity and frequency of infections decreased significantly\[[@CR422]\]Case reportIVIg with antibiotics, chloroquine, and PDA 6-year-old with HIGM and severe recurrent respiratory infectionsMild improvement with a decrease in the inflammatory infiltrate in thoracoscopic biopsy\[[@CR423]\]Case reportIVIg and prophylactic antibiotic therapyA 6 years old with CD40 ligand deficiency, chronic neutropenia, and HIGMManagement of neutropenia, better quality of life with decreasing occurrence of infection\[[@CR424]\]Case reportIVIgA 5-month-old boy with HIGM and severe pneumonia refractory to antibioticsHis pneumonia improved; after that, he had no recurrent infectionsTransient hypogamma of infancy (THI)\[[@CR425]\]Case reportIVIg every 4 weeks1-year-old girl with THI and *Staphylococcus aureus* sepsis refractory to antibioticsGradual improvement\[[@CR426]\]Case reportTreated with antibiotics and IVIg1-year-old boy with THI and recurrent sepsisFewer infectionsSevere combined immunodeficiency (SCID)\[[@CR427]\]Case controlMonthly IVIg45 children surviving BMT for SCIDEffective as adjuvant for BMTCommon Variable Immune Deficiency (CVID)\[[@CR428]\]Case seriesThe number of pneumonia episodes was compared prior to and after initiation of IVIg maintenance therapy for 6.6 ± 5.2 years (0.3--0.4 g/kg every 3 to 4 weeks)50 patients with confirmed CVIDPrior to IVIg therapy, 84% of patients had an episode of pneumonia, and 22% had recurrent pneumonias; following IVIg administration, 22% of the patients have acquired pneumonia; this change was found to be statistically significant (*p* \< 0.001)\[[@CR32]\]Case seriesData were collected retrospectively; all the patients were treated by 3 modalities: no IVIg, low-dose IVIg (0.2 g/kg every 3 weeks), and standard-dose IVIg (0.4 g/kg every 3 weeks)7 patients diagnosed with CVIDNumber of infections per patient-year was 5 in the no-IVIg period, 2.79 in the low-dose period (*p* = 0.002), and 1.53 in the standard-dose period (*p* = 0.02); lower respiratory tract infections were markedly decreased due to IVIg therapy\[[@CR31]\]Case seriesIVIg (Sandoglobulin and/or Nordimmune), 0.4 g/kg every 3 to 4 weeks; the follow-up period was 41.5 ± 35.4 months26 patients diagnosed with CVIDIVIg therapy was associated with significant decrease of annual hospitalization due to pneumonia: from 88.5% to 46% (*p* = 0.0025); a significant decrease of total hospital admissions was also observed (from 3.4 to 0.7 per year, *p* \< 0.0005)

X-linked agammaglobulinemia {#Sec125}
---------------------------

### Level of evidence B {#d29e11828}

Retrospective analyses revealed that IVIg is beneficial in terms of reduction of acute and chronic infections and days of stay in the hospital. Intravenous route is preferred over intramuscular administration of immunoglobulin and the number and severity of complications are inversely correlated with the dose of IVIg (*strength of recommendation I*).

Wiscott--Aldrich syndrome {#Sec126}
-------------------------

### Level of evidence C {#d29e11839}

Despite relatively low evidence of effectiveness of IVIg, the majority of WAS patients are treated with IVIg, which appears to be effective in reduction of acute and chronic infections in these immunodeficient patients (*strength of recommendation IIa*).

Hyper-IgE syndrome (job syndrome) {#Sec127}
---------------------------------

### Level of evidence C {#d29e11850}

There is weak evidence that IVIg is useful in the treatment of hyper-IgE syndrome. IVIg may be tried in cases in which recurrent live-threatening diseases cannot be controlled by antibiotic prophylaxis (*strength of recommendation IIb*).

IgG subclass deficiencies {#Sec128}
-------------------------

### Level of evidence C {#d29e11861}

There is scarce evidence that IVIg is useful in the treatment of IgG subclass deficiencies. Most of the experience reported is patients with IgG2 deficiency. In our opinion, when antibiotic treatment is not effective, IVIg would be a reasonable alternative (*strength of recommendation IIb*).

Specific antibody deficiency {#Sec129}
----------------------------

### Level of evidence B {#d29e11872}

This is a heterogeneous group. Specific deficiency of antibodies after vaccination has been found to correlate with infection susceptibility. Most of the published experience regarding IVIg is in patients with deficiency of antibodies to capsular polysaccharide. IVIg has been reported to be beneficial in some cases. This is not surprising as antibodies to bacterial capsular polysaccharide are contained in IVIg \[[@CR30]\]. The evidence for the use of IVIg in specific antibody deficiency is not strong but might be warranted when recurrent infection is present and it is possible to demonstrate low antibody responses to a relevant vaccine (*strength of recommendation IIa*).

Hyper-immunoglobulin-G syndrome {#Sec130}
-------------------------------

### Level of evidence B {#d29e11886}

The hyper-IgM syndrome (HIGM) is a rare hereditary immune deficiency, characterized by a low or nil level of IgG and IgA and a normal or increased level of IgM, predominately affecting boys. Its clinical manifestations are dominated by recurrent infection, notably of the digestive tube, the ears, nose, and throat and the lungs. IVIg may be considered to treat patients with HIGM and recurrent infections (*strength of recommendation I*).

Transient hypogammaglobulinemia of infancy {#Sec131}
------------------------------------------

### Level of evidence C {#d29e11897}

Transient hypogammaglobulinemia of infancy is characterized by a prolongation and accentuation of the physiologic hypogammaglobulinemia normally occurring during the first 3 to 6 months of life and recovers spontaneously between 18 and 36 months of age. Infants with transient hyogammaglobulinemia of infancy (THI) may remain asymptomatic or develop recurrent sinopulmonary infections, but severe or life-threatening infections are rare. In general, supportive and antimicrobial therapies are sufficient management for the treatment of specific infections in patients with THI. In cases in which infections are severe or refractory to conventional therapy, IVIg is sometimes considered although literature reports are lacking (*strength of recommendation I*).

Severe combined immunodeficiency {#Sec132}
--------------------------------

### Level of evidence B {#d29e11908}

SCID is a severe form of heritable immunodeficiency in which both "arms" of the adaptive immune system are defected. These babies, if untreated, usually die within 1 year due to severe recurrent infections. Treatment with BMT is successful, and IVIg is used as an adjuvant for this therapy (*strength of recommendation I*).

Common variable immune deficiency {#Sec133}
---------------------------------

### Level of evidence C {#d29e11919}

Common variable immune deficiency (CVID) is an idiopathic hypoimmunoglobulinemia. World Health Organization diagnostic criteria are well established \[[@CR31]\]. Both B and T cells dysfunction have been observed \[[@CR32]\]. There are both theoretical logic and experimental evidences that support IVIg administration in CVID (*strength of recommendation IIb*).

Primary phagocytic defect {#Sec134}
-------------------------

Many different genetic diseases will ultimately result in primary phagocytic defect: cyclic neutropenia, severe congenital neutropenia, Shwachman--Diamond syndrome, leukocyte adhesion deficiency, Rac2 deficiency, interferon-γ and IL-12 defects, chronic granulomatous disease, myeloperoxidase deficiency, Chediak--Higashi syndrome, and neutrophil-specific granule deficiency \[[@CR33]\]. An extensive PubMed-based search revealed little if any information regarding the efficacy of IVIg in the above entities.

IgA deficiency {#Sec135}
--------------

IgA deficiency may be associated with preventable anaphylaxis or anaphylactoid reaction following IVIg transfusion \[[@CR34]\]. This adverse reaction is encountered in patients with selective IgA deficiency and high titer of anti-IgA antibodies. In those patients, anaphylaxis can be avoided by the use of IgA-depleted IVIg preparation \[[@CR35]\].

Discussion {#Sec136}
==========

This article summarizes most of the studies dealing with IVIg administration that were publicized until recently. We have included an array of clinical conditions, some in which the use of IVIg is expected according to their pathogenesis, such as primary immunodeficiencies and rheumatic diseases, and others somewhat less obvious indications including cardiac and oncologic diseases. In some diseases, the usage of IVIg was found to be highly recommended (with a level of evidence A and strength of recommendation I): Kawasaki disease, acquired hypogammaglobulinemia, juvenile rheumatoid arthritis, hemolytic disease of the newborn, acute immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and Guillain--Barré syndrome. For many other diseases, treatment with IVIg was found effective as well, but this was less well established, either due to a lack of well-designed studies or due to conflicting evidence among them. In some diseases, there is a strong recommendation against using IVIg (with a level of evidence A and strength of recommendation III): stem cell/bone marrow transplantation, inclusion body myositis, recurrent pregnancy loss due to antiphospholipid syndrome, optic neuritis, and intractable childhood epilepsy. Nevertheless, the effectiveness of IVIg in such a large span of diseases fortifies the accumulating evidence that many pathological conditions are autoimmune mediated.

y/o

:   year old

IVIg

:   intravenous immunoglobulins

RCT

:   randomized controlled trial

IFN

:   interferon

CS

:   corticosteroids

BMT

:   bone marrow transplantation

HCV

:   hepatitis C virus

PD

:   prednisone

CP

:   cyclophosphamide

CNS

:   central nervous system

MPGN

:   membranous-proliferative glomerulonephritis

MP

:   methylprednisolone

PP

:   plasmapheresis

LMWH

:   low-molecular-weight heparin

LDA

:   low-dose aspirin

NYHA

:   New York Heart Association

EF

:   ejection fraction

CHF

:   congestive heart failure

DCM

:   dilated cardiomyopathy

PPCM

:   peripartum cardiomyopathy

CIP

:   chronic idiopathic pericarditis

NLE

:   neonatal lupus erythematosus

MMP

:   mucous membrane pemphigoid

EDSS

:   expanded disability status scale

VLCFA

:   very-long-chain fatty acids

GTOE

:   glycerol trioleate/erucic supplementation

INCAT

:   inflammatory neuropathy cause and treatment disability score

MCV

:   motor conduction velocities

CMAP

:   compound muscle action potential

MRC scale

:   medical research council

RRMS

:   relapsing--remitting multiple sclerosis

Ref

:   reference

MTX

:   methotrexate

MMF

:   mycophenolate mofetil

CAA

:   coronary artery aneurysm
